JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL. 76, NO. 25, 2020 ª 2020 THE AUTHORS. PUBLISHED BY ELSEVIER ON BEHALF OF THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION. THIS IS AN OPEN ACCESS ARTICLE UNDER THE CC BY LICENSE (http://creativecommons.org/licenses/by/4.0/). JACC STATE-OF-THE-ART REVIEW Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019 Update From the GBD 2019 Study Gregory A. Roth, MD, MPH,a George A. Mensah, MD,b Catherine O. Johnson, PHD, MPH,c Giovanni Addolorato, MD,d Enrico Ammirati, MD, PHD,e Larry M. Baddour, MD,f Noël C. Barengo, MD, PHD, MPH,g Andrea Z. Beaton, MD,h Emelia J. Benjamin, MD, SCM,i Catherine P. Benziger, MD,j Aimé Bonny, MD, MSC,k Michael Brauer, SCD,l Marianne Brodmann, MD,m Thomas J. Cahill, MBBS, DPHIL,n Jonathan Carapetis, MBBS, PHD,o Alberico L. Catapano, PHD,p Sumeet S. Chugh, MD,q Leslie T. Cooper, MD,r Josef Coresh, MD, PHD,s Michael Criqui, MD, MPH,t Nicole DeCleene, BS,u Kim A. Eagle, MD,u Sophia Emmons-Bell, BA,c Valery L. Feigin, MD, MSC, PHD,a Joaquim Fernández-Solà, MD, PHD,v Gerry Fowkes, PHD,w Emmanuela Gakidou, MSC, PHD,a Scott M. Grundy, MD, PHD,x Feng J. He, PHD,y George Howard, DRPH,z Frank Hu, MD, PHD,aa Lesley Inker, MD, MS,bb Ganesan Karthikeyan, MD,cc Nicholas Kassebaum, MD,a Walter Koroshetz, MD,dd Carl Lavie, MD,ee Donald Lloyd-Jones, MD, SCM,ff Hong S. Lu, MD, PHD,gg Antonio Mirijello, MD,hh Awoke Misganaw Temesgen, PHD,c Ali Mokdad, PHD,c Andrew E. Moran, MD,ii Paul Muntner, PHD,z Jagat Narula, MD, PHD,jj Bruce Neal, MBCHB,kk Mpiko Ntsekhe, MD, PHD,ll Glaucia Moraes de Oliveira, MSC, PHD,mm Catherine Otto, MD,a Mayowa Owolabi, MBBS, MSC, DMED,nn Michael Pratt, MD, MPH,t Sanjay Rajagopalan, MD,oo Marissa Reitsma, PHD,pp Antonio Luiz P. Ribeiro, MD,qq Nancy Rigotti, MD,rr Anthony Rodgers, MD,ss,tt Craig Sable, MD,uu Saate Shakil, MD,a Karen Sliwa-Hahnle, MD, PHD,ll Benjamin Stark, MA,a Johan Sundström, MD, PHD,vv Patrick Timpel, MSC,ww Imad M. Tleyjeh, MD, MSC,xx Marco Valgimigli, MD, PHD,yy Theo Vos, MD, PHD,a Paul K. Whelton, MD, MSC,zz Magdi Yacoub, MD, PHD,tt Liesl Zuhlke, MBCHB, PHD,ll Christopher Murray, DPHIL,c Valentin Fuster, MD, PHD,jj,aaa for the GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group* From the aUniversity of Washington, Seattle, Washington, USA; bNational Heart, Lung, and Blood Institute (NHLBI), Bethesda, Maryland, USA; cUniversity of Washington, Institute for Health Metrics and Evaluation, Seattle, Washington, USA; dCatholic University of Rome, Rome, Italy; eDe Gasperis Cardio Center and Transplant Center, Niguarda Hospital, Milan, Italy; fMayo Clinic, Rochester, Minnesota, USA; gHerbert Wertheim College of Medicine, Florida International University, Miami, Florida, USA; h Cincinnati Children’s Hospital, Cincinnati, Ohio, USA; iBoston University School of Public Health, Boston, Massachusetts, USA; j Essentia Health, Duluth, Minnesota, USA; kDistrict Hospital of Bonassama-University of Douala, Douala, Cameroon; lUniversity of British Columbia, Vancouver, British Columbia, Canada; mMedical University of Graz, Graz, Austria; nNewpath Partners LLC, Boston, Massachusetts, USA; oTelethon Kids Institute, Nedlands, Western Australia, Australia; pUniversity of Milano, Milan, Italy; q Cedars-Sinai, Smidt Heart Institute, Los Angeles, California, USA; rMayo Clinic, Jacksonville, Florida, USA; sJohns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA; tUniversity of California at San Diego, San Diego, California, USA; u The University of Michigan Samuel and Jean Frankel Cardiovascular Center, Ann Arbor, Michigan, USA; vBarnaclinicþ Grup Hospital Clinic, Barcelona, Spain; wUniversity of Edinburgh, Edinburgh, United Kingdom; xUniversity of Texas Southwestern Medical Center, Dallas, Texas, USA; yQueen Mary University of London, London, United Kingdom; zUniversity of Alabama at Birmingham School of Public Health, Birmingham, Alabama, USA; aaHarvard Medical School, Boston, Massachusetts, USA; bbTufts Medical Center, Boston, Massachusetts, USA; ccCardiothoracic Sciences Centre, All India Institute of Medical Sciences, New Delhi, Listen to this manuscript’s audio summary by Editor-in-Chief Dr. Valentin Fuster on JACC.org. India; ddNational Institute of Neurological Disorders and Stroke, Bethesda, Maryland, USA; eeOchsner Health, New Orleans, Louisiana, USA; ffNorthwestern University Feinberg School of Medicine, Chicago, Illinois, USA; ggUniversity of Kentucky College of Medicine, Lexington, Kentucky, USA; hhIRCCS Casa Sollievo della Sofferenza Hospital, Department of Medical Sciences, San Giovanni Rotondo, Italy; iiColumbia University Irving Medical Center, New York, New York, USA; jjIcahn School of Medicine at Mount Sinai, New York, New York, USA; kkThe University of Sydney School of Medicine, Sydney, New South Wales, Australia; ll University of Cape Town, Cape Town, South Africa; mmUniversidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; nnUni- versity of Ibadan, Ibadan, Oyo State, Nigeria; ooCase Western Reserve University School of Medicine, Cleveland, Ohio, USA; pp Stanford University School of Medicine, Stanford, California, USA; qqUniversidade Federal de Minas Gerais, Minas Gerais, Brazil; rr Massachusetts General Hospital, Boston, Massachusetts, USA; ssThe George Institute for Global Health, Newtown, New South Wales, Australia; ttImperial College of London, London, United Kingdom; uuChildren’s National Hospital, Washington, DC, USA; vv Uppsala University, Uppsala, Sweden; wwDresden University of Technology, Dresden, Germany; xxKing Fahd Medical City, ISSN 0735-1097 https://doi.org/10.1016/j.jacc.2020.11.010 Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 2983 Global Burden of Cardiovascular Diseases ABBREVIATIONS ABSTRACT AND ACRONYMS Cardiovascular diseases (CVDs), principally ischemic heart disease (IHD) and stroke, are the leading cause of AC = alcoholic cardiomyopathy global mortality and a major contributor to disability. This paper reviews the magnitude of total CVD burden, AF = atrial fibrillation including 13 underlying causes of cardiovascular death and 9 related risk factors, using estimates from the AFL = atrial flutter Global Burden of Disease (GBD) Study 2019. GBD, an ongoing multinational collaboration to provide BMI = body mass index comparable and consistent estimates of population health over time, used all available population-level data CAVD = calcific aortic valve sources on incidence, prevalence, case fatality, mortality, and health risks to produce estimates for 204 disease countries and territories from 1990 to 2019. CHA = congenital heart Prevalent cases of total CVD nearly doubled from 271 million (95% uncertainty interval [UI]: 257 to anomalies 285 million) in 1990 to 523 million (95% UI: 497 to 550 million) in 2019, and the number of CVD deaths CKD = chronic kidney disease steadily increased from 12.1 million (95% UI:11.4 to 12.6 million) in 1990, reaching 18.6 million (95% UI: 17.1 to CVD = cardiovascular disease 19.7 million) in 2019. The global trends for disability-adjusted life years (DALYs) and years of life lost also DALYs = disability-adjusted increased significantly, and years lived with disability doubled from 17.7 million (95% UI: 12.9 to 22.5 million) to life years 34.4 million (95% UI:24.9 to 43.6 million) over that period. The total number of DALYs due to IHD has risen GBD = Global Burden of steadily since 1990, reaching 182 million (95% UI: 170 to 194 million) DALYs, 9.14 million (95% UI: 8.40 to Diseases, Injuries, and Risk Factors Study 9.74 million) deaths in the year 2019, and 197 million (95% UI: 178 to 220 million) prevalent cases of IHD in HAP = household air pollution 2019. The total number of DALYs due to stroke has risen steadily since 1990, reaching 143 million (95% UI: 133 HHD = hypertensive heart to 153 million) DALYs, 6.55 million (95% UI: 6.00 to 7.02 million) deaths in the year 2019, and 101 million (95% disease UI: 93.2 to 111 million) prevalent cases of stroke in 2019. HICs = high-income countries Cardiovascular diseases remain the leading cause of disease burden in the world. CVD burden continues its ICD = International decades-long rise for almost all countries outside high-income countries, and alarmingly, the age-standardized Classification of Diseases rate of CVD has begun to rise in some locations where it was previously declining in high-income countries. IHD = ischemic heart disease There is an urgent need to focus on implementing existing cost-effective policies and interventions if the world IKF = impaired kidney function is to meet the targets for Sustainable Development Goal 3 and achieve a 30% reduction in premature mortality IS = ischemic stroke due to noncommunicable diseases. (J Am Coll Cardiol 2020;76:2982–3021) © 2020 The Authors. Published by LDL = low-density lipoprotein Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC LMICs = low- and middle- BY license (http://creativecommons.org/licenses/by/4.0/). income countries C LPA = low physical activity ardiovascular disease (CVD) remains a major This paper explores CVD trends from 1990 cause of premature mortality and rising to 2019 and examines the extent to which health care costs (1,2). Cardiometabolic, population growth and aging explain the behavioral, environmental, and social risk factors observed trends, sex differences, are major drivers of CVD. Consistent, comparable, regional patterns and how the epidemiology and systematic analysis of long-term trends and pat- of the disease itself is changing. These trends terns in global CVD are essential to guide public pol- show us where in the world CVD mortality icy and provide benchmarks for decision makers. and burden are increasing or declining and Beginning with ischemic heart disease (IHD) and where progress has stalled (3). For each of the stroke, this article provides information on the contributing causes of cardiovascular death burden of CVD, including 13 underlying causes of car- and risk factors examined, we identify which diovascular death and 9 related risk factors at the regions and countries have the highest and global, regional, and national levels (Supplemental lowest estimates of prevalent cases and Figure 1). number of deaths, as well as summary Riyadh, Saudi Arabia; yyInselspital, University Hospital Bern, Bern, Switzerland; zzTulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana, USA; and the aaaCentro Nacional de Investigaciones Cardiovasculares, Madrid, Spain. *A complete list of the the GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group is available in the Supplemental Appendix. The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. Manuscript received October 29, 2020; revised manuscript received November 6, 2020, accepted November 6, 2020. and MV = mitral valve PAD = peripheral artery disease PM = particulate matter RHD = rheumatic heart disease SBP = systolic blood pressure SDI = sociodemographic index TMREL = theoretical minimum risk exposure level UI = uncertainty interval YLDs = years lived with disability YLLs = years of life lost 2984 Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases measures including number of years of life lost (YLLs), number of years lived with disability (YLDs), and the magnitude and temporal trends in disabilityadjusted life years (DALYs) (1). For each section, the article also addresses how the summary measures of health and disease discussed inform investments in cardiovascular research, their implications for clinical and public health practice, and implications for health system development and national and regional policy. To improve accessibility across a wide range of audiences, we have structured the review such that each section can be read independently for those most interested in a subset of causes or risks. Discussion pertinent to each topic is included within HIGHLIGHTS  The burden of CVD, in number of DALYs and deaths, continues to increase globally.  CVD burden attributable to modifiable risk factors continues to increase globally.  Countries should invest in existing costeffective public health programs and clinical interventions to target modifiable risks, promote healthy aging across the lifespan, and reduce disability and premature death due to CVD. every section. This article is a collaborative effort involving the Journal of the American College of Cardiology, the National Heart, Lung, and Blood Insti- Myocardial infarction was defined according to the tute, and the Institute for Health Metrics and Fourth Universal Definition of Myocardial Infarction Evaluation at the University of Washington designed and was adjusted to include out-of-hospital sudden to provide crucial population-level information that cardiac death. Stable angina was defined according to can guide action for CVD and risk factor prevention, the Rose Angina Questionnaire. Stroke was defined treatment, and control (2). according to the World Health Organization definition and was estimated separately for 3 subcategories: 1) GLOBAL BURDEN OF DISEASE ischemic stroke (IS); 2) intracerebral hemorrhage; and STUDY METHODS 3) subarachnoid hemorrhage (7). Lower extremity GBD 2019 is a multinational collaborative research ankle brachial index of <0.9. Symptomatic PAD was study that estimates disease burden for every country defined as self-report of symptoms of claudication in the world (1,4). The study is an ongoing effort, among those with an ankle brachial index of <0.9. peripheral artery disease (PAD) was defined by an updated annually, and is designed to allow for Atrial fibrillation (AF) and atrial flutter (AFL) were consistent comparison over time from 1990 to 2019, defined by electrocardiogram. Hypertensive heart by age and sex, and across locations. The study pro- disease (HHD) was defined as symptomatic heart duces standard epidemiological measures such as failure due to the direct and long-term effects of hy- incidence, prevalence, and death rates as well as pertension. Cardiomyopathy was defined as symp- summary measures of health, such as DALYs. DALYs tomatic heart failure due to primary myocardial represent the sum of years of life lost prematurely disease or toxin exposure to the myocardium, such as and years lived with disability; can be estimated from alcohol. Acute myocarditis was defined as an acute life tables, estimates of prevalence, and disability and weights; and may be expressed as counts or rates. inflammation using health system administrative Annual updates to the study include new diseases, data. Endocarditis and rheumatic heart disease (RHD) new data sources, and updates to methods. All results were defined by their clinical diagnosis. Estimates of are available via the GBD Compare website (5), and all RHD include cases identified by clinical history and input data is identified via the Global Health Data physical examination, Exchange website (6). The study is performed in standard echocardiographic compliance with Guidelines for Accurate and Trans- disease. time-limited condition due including to myocardial auscultation criteria for or definite parent Health Estimates Reporting (GATHER) guide- Mortality was estimated by using vital registration lines for reporting health estimates (1). Detailed data coded to the International Classification of Dis- methods ease (ICD) system or household mortality surveys of GBD 2019 are reported in the Supplemental Appendix and summarized here. Each CVD cause and related health states were known as verbal autopsy. Statistical methods were used to increase the comparability of mortality data identified with standard case definitions. IHD repre- sources, including the reclassification of codes that sented acute myocardial infarction, chronic stable are nonspecific or unspecified, noise reduction algo- angina, chronic IHD, and heart failure due to IHD. rithms, and Bayesian geospatial regression software Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases (CODem, the cause of death ensemble model, Insti- number of CVD deaths steadily increased from 12.1 tute for Health Metrics and Evaluation, Seattle, million (95% UI: 11.4 to 12.6 million) in 1990, reaching Washington) that used location-specific covariates to 18.6 million (95% UI: 17.1 to 19.7 million) in 2019 create smoothed time trends for 204 countries and (Figure 1A). The global trends for DALYs and YLLs territories by borrowing strength over age, space, and also increased significantly, and YLDs doubled from time. GBD 2019 allowed for the production of esti- 17.7 million (95% UI: 12.9 to 22.5 million) to 34.4 mates with uncertainty intervals (UIs) for all locations million in every year, even when data were sparse or missing. that period. (95% UI: 24.9 to 43.6 million) over Disease incidence and prevalence were produced by At the country level, age-standardized mortality using a broad range of population-representative data rates for total CVD were highest in Uzbekistan, Solo- sources identified by literature review and via study mon Islands, and Tajikistan and were lowest in collaborations, including scientific reports of cohorts France, Peru, and Japan, where rates were 6-fold and registries, population surveys, microdata from lower in 2019. From 1990 to 2019, large declines in registry and cohort studies, and health system the age-standardized rates of death, DALYs, and administrative data. Consistent disease estimates YLLs, together with small gradual reductions in age- were state- standardized rates for prevalent cases and YLDs, transition disease modeling software, DisMod-MR suggest that population growth and aging are major (Institute for Health Metrics and Evaluation), and drivers of the increase in total CVD (Figure 1B). produced Bayesian by using epidemiologic meta-regression MR-BRT In 2019, total CVD DALYs were higher in men than (Institute for Health Metrics and Evaluation), that women before age 80 to 84 years (Supplemental adjusted for study-level differences in measurement Figure 2). After this age, the pattern reverses. The methods and case definitions. Risk factor exposures sex differences in DALYs is most striking between were estimated by using population-representative ages 30 and 60 years (men greater) and age >80 years survey geospatial (women greater). The excess CVD deaths in women Gaussian process regression models that borrowed beginning at ages 80 to 84 years should focus atten- strength across time and geography. tion to cause-specific mortality at older ages and have and surveillance software, data and DALYs were calculated as the sum of YLLs, based implications for secondary prevention strategies. on a reference maximum observed life expectancy, Among women, the age-standardized rates for and YLDs based on standardized disability weights DALYs were highest in Central Asia, Oceania, North for each health state. Population-attributable frac- Africa and the Middle East, and Eastern Europe; and tions were calculated independently by risk factor by lowest in High-Income Asia Pacific, Australasia, and using risk exposures, estimates of relative risk based Western Europe (Supplemental Figure 3). Among on meta-analyses, and theoretical minimum risk men, age-standardized rates for DALYs were highest levels pair. in Central Asia, Eastern Europe, and Oceania; and Adjustment was made for comorbidity by simulating lowest in High-Income Asia Pacific, Australasia, 40,000 individuals in each age-sex-country-year Western Europe, and Andean Latin America. At the exposed to the independent probability of acquiring country level, the highest age-standardized rates conditions based on their prevalence. The 95% UIs were estimated for many of the islands of Oceania, reported for each estimate used 1,000 draws from the Uzbekistan, and Afghanistan, while the lowest rates posterior distribution of models, reported as the 2.5th for DALYs were seen in Japan, France, and Israel determined for each risk-outcome and 97.5th values of the distribution. Age standardi- (Supplemental Figure 4). These regional and national zation was performed via the direct method, applying differences in total CVD burden and mortality reflect a global age structure from the year 2019. The Uni- differences in prevalence of CVD risk factors as well versity of Washington Institutional Review Board as access to health care (8). Differences in access to Committee approved the Global Burden of Diseases, effective primary and secondary prevention strate- Injuries, and Risk Factors Study (STUDY00009060). gies may also play a role in differences in total CVD burden, especially in low- and middle-income coun- CARDIOVASCULAR DISEASES tries (LMICs) (9). TOTAL CVDs. CVDs are common, have poor survival, plications for clinical practice and public health pol- Global patterns of total CVD have significant imand are increasing worldwide (Central Illustration). icy development (10). Prevalent cases of total CVD are Prevalent cases of total CVD nearly doubled from 271 likely to increase substantially as a result of popula- million (95% UI: 257 to 285 million) in 1990 to 523 tion growth and aging, especially in Northern Africa million (95% UI: 497 to 550 million) in 2019, and the and Western Asia, Central and Southern Asia, Latin 2985 2986 Roth et al. JACC VOL. 76, NO. 25, 2020 Global Burden of Cardiovascular Diseases DECEMBER 22, 2020:2982–3021 C E N T R A L IL L U ST R A T I O N Cardiovascular Disease Burden Across Time, Location, Cause, and Risk Factor Roth, G.A. et al. J Am Coll Cardiol. 2020;76(25):2982–3021. Percent Change in Age-Standardized CVD Death Rate from 2010-2019. Map of the percent change in age-standardized CVD mortality rate from 2010 to 2019.Number of CVD Deaths. Total number of deaths due to CVD by sex, 1990 to 2019; total number of deaths due to CVD in 2010 and 2019 among the countries with the highest number of CVD deaths in 2019. Proportion of CVD Deaths by Cause (2019). Proportion of total CVD deaths in 2019 by underlying causes. CVD Burden Attributable to Modifiable Risk Factors. Comparison of the rankings of CVD DALYs attributable to modifiable risk factors in 1990 and 2019. CVD ¼ cardiovascular disease; DALYs ¼ disability-adjusted life years; LDL ¼ low-density lipoprotein. Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases F I G U R E 1 Total Numbers and Rates of Cardiovascular Diseases A B DALYs DALYs per 100,000 8,000 400 300 6,000 200 4,000 100 2,000 0 0 1990 2000 2010 1990 2019 2010 2019 Deaths per 100,000 Deaths 20 400 15 300 10 200 5 100 0 0 2000 2010 Prevalence 600 400 200 0 1990 2000 2010 1990 2019 2019 Rate per 100,000 Persons 1990 Number (in Millions) 2000 2000 2010 2019 Prevalent cases per 100,000 8,000 6,000 4,000 2,000 0 1990 2000 2010 2019 YLDs per 100,000 YLDs 600 40 30 400 20 200 10 0 0 1990 2000 2010 1990 2019 YLLs 2000 2010 2019 YLLs per 100,000 400 8,000 300 6,000 200 4,000 100 2,000 0 0 1990 2000 2010 Year 2019 1990 Age-Standardized All Ages 2000 2010 Year 2019 (A) Total number of DALYs, deaths, prevalent cases, YLDs, and YLLs due to cardiovascular diseases, 1990 to 2019. Shaded regions represent 95% uncertainty intervals. (B) Age-standardized and all-ages DALY, death, prevalence, YLD, and YLL rates of cardiovascular diseases, 1990 to 2019. Shaded regions represent 95% uncertainty intervals. DALYs ¼ disability-adjusted life years; YLDs ¼ years lived with disability; YLLs ¼ years of life lost. 2987 2988 Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases America and the Caribbean, and Eastern and South- on delivering effective interventions that will reverse eastern Asia, where the share of older persons is these trends, including those that prevent and control projected to double between 2019 and 2050 (11,12). diabetes, decrease obesity and high cholesterol, Increased attention to promoting ideal cardiovascular improve diet and physical activity, reduce tobacco health and healthy aging across the lifespan is and excessive alcohol use, integrate “polypills” for necessary (13). Equally importantly, the time has elevated blood pressure and related conditions, come to implement feasible and affordable strategies improve pre- and in-hospital care for acute coronary for the prevention and control of CVD and to monitor syndrome, and improve survival and quality of life for results (14). those living with the long-term sequelae of IHD, ISCHEMIC HEART DISEASE. The total number of including heart failure. Social and economic factors DALYs due to IHD has risen steadily since 1990, remain fundamental drivers of IHD, suggesting that reaching 182 million (95% UI: 170 to 194 million) multisectoral interventions are needed to eradicate DALYs and 9.14 million (95% UI: 8.40 to 9.74 million) this disease (15). deaths in the year 2019 (Figure 2A). GBD 2019 esti- STROKE. The total number of prevalent strokes, mated 197 million (95% UI: 178 to 220 million) prev- deaths, and DALYs due to stroke increased steadily alent cases of IHD in 2019. from 1990, reaching 101 million (95% UI: 93.2 to 111 Global age-standardized rates for DALYs, deaths, million) prevalent (85.3% [95% UI: 82.6% to 88.2%] and prevalent cases declined over this time period, increase) stroke survivors, 6.55 million (95% UI: 6.00 indicating that, on average, global increases in IHD to 7.02 million) deaths from stroke (43.3% [95% UI: have been due to population growth and aging, 31.0% to 55.4%] increase), and 143 million (95% UI: although even the age-standardized death rate is 133 to 153 million) DALYs due to stroke (32.4% [95% estimated to be increasing in many locations across UI: 22.0% to 42.2%] increase) in 2019, with the bulk of South, East, and Southeastern Asia, including China the (Figure 2B). Increasing absolute numbers of incident (Supplemental Figures 8A and 9A). Of 12.2 million and prevalent IHD cases in most countries mean that (95% UI: 11.0 to 13.6 million) incident stroke cases, national address 7.63 million (95% UI: 6.57 to 8.96 million) (62.4%) increasing demand for IHD-related preventive and were IS, 3.41 million (95% UI: 2.97 to 3.91 million) therapeutic services as these trends continue. (27.9%) were intracerebral hemorrhages, and 1.18 health systems will need to burden (95% outside UI: of At the global level, substantially more total DALYs million due to IHD were experienced by men than women. were 1.01 IHD DALYs rose rapidly for men beginning at age Figures 10A, 11A, and 12A). subarachnoid the to high-income 1.39 hemorrhages million) world (9.7%) (Supplemental 30 years (Supplemental Figure 5). Men ages 45 to Globally, age-standardized rates for deaths and 49 years had almost as many DALYs due to IHD as DALYs due to stroke substantially declined over the women ages 65 to 69 years. same period of time (Supplemental Figures 8B, 10B, Age-standardized DALY rates due to IHD were 11B, and 12B), suggesting that: 1) preventive mea- highest in Eastern Europe, Central Asia, Oceania, and sures are very effective at lowering risk of both the Middle East/North Africa regions (Supplemental ischemic and hemorrhagic stroke; and 2) on average, Figure 6). At the country level, extremely high rates global increases in stroke burden have been largely were estimated for Uzbekistan, Ukraine, Tajikistan, due to population growth and aging. Importantly, and many of the islands of Oceania, with the lowest age-standardized rates for prevalence of stroke sur- levels in Japan, Republic of Korea, and France vivors have increased since 1990 in several locations (Supplemental Figure 7). Higher exposure to risks including in China, Indonesia, and parts of the United including tobacco and excessive alcohol use and States. Age-standardized death rates also increased in restricted access to preventive health care may partly some explain these patterns. Philippines. locations, including Indonesia and the IHD remains a major threat to public health, and Age-standardized rates of DALYs and deaths due to overall burden is increasing globally. In some loca- stroke were substantially greater in men compared to tions over the past 5 years, including parts of the women, but prevalence was greater in women, sug- United States and United Kingdom, age-standardized gesting the possibility of greater risk of death and IHD death rates are increasing, suggesting that long- disability in men but better stroke survival in women. term declines in IHD due to improved prevention Similar patterns were observed in men and women and health care are no longer occurring in these lo- with IS, intracerebral hemorrhage, and subarachnoid cations. Health systems and countries need to focus hemorrhage. Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases F I G U R E 2 Total Numbers and Rates of Ischemic Heart Disease A B DALYs DALYs per 100,000 200 3,000 150 100 2,000 50 1,000 0 0 1990 2000 2010 1990 2019 2010 2019 Deaths per 100,000 Deaths 10.0 200 7.5 150 5.0 100 2.5 50 0.0 0 2000 2010 Prevalence 200 150 100 50 0 1990 2000 2010 1990 2019 2019 Rate per 100,000 Persons 1990 Number (in Millions) 2000 2000 2010 2019 Prevalent cases per 100,000 3,000 2,000 1,000 0 1990 2000 2010 2019 YLDs per 100,000 YLDs 8 6 90 4 60 2 30 0 0 1990 2000 2010 1990 2019 YLLs 2000 2010 2019 YLLs per 100,000 200 3,000 150 100 2,000 50 1,000 0 0 1990 2000 2010 Year 2019 1990 Age-Standardized All Ages 2000 2010 Year 2019 (A) Total number of DALYs, deaths, prevalent cases, YLDs, and YLLs due to ischemic heart disease, 1990 to 2019. Shaded regions represent 95% uncertainty intervals. (B) Age-standardized and all-ages DALY, death, prevalence, YLD, and YLL rates of ischemic heart disease, 1990 to 2019. Shaded regions represent 95% uncertainty intervals. Abbreviations as in Figure 1. 2989 2990 Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases F I G U R E 3 Map of Age-Standardized Prevalence of Stroke Survivors in 2019 There is tremendous regional disparity in the burden approaches for delivering stroke prevention that can of stroke. Age-standardized rates of deaths and reverse these trends, including strategies to provide DALYs due to stroke were highest in Oceania, Central equal access to quality health care and prevention Asia, East Asia, Southeast Asia, Eastern Europe, and across all populations, and proven effective in- sub-Saharan Africa (Supplemental Figure 13), and terventions that reduce mortality and improve out- prevalence of stroke survivors was highest in Oce- comes post-stroke. ania, Southeast Asia, East Asia, and the Middle East/ North Africa regions (Figure 3). These data suggest HYPERTENSIVE HEART DISEASE. The global preva- that applying preventive strategies, such as treatment lence of HHD has risen steadily over the last 3 de- of elevated blood pressure and cholesterol levels, can cades, as have the total number of deaths, DALYs, have major health benefits where stroke burden re- YLLs, and YLDs due to this disease. In 2019, HHD was mains high, especially in those regions that did not the main cause of 1.16 million (95% UI: 0.86 to 1.28 show substantial decline over the past decades (i.e., million) deaths and 21.5 million (95% UI: 16.4 to 23.9 Central Asia, Southern sub-Saharan Africa). million) DALYs annually, with a global prevalence of Stroke remains the second-leading cause of death, and stroke burden in terms of DALYs is increasing. 18.6 million (95% UI: 13.5 to 24.9 million) cases (Supplemental Figure 14A). Primary stroke prevention strategies are not suffi- The age-standardized prevalence and YLDs of HHD ciently effective as currently implemented in many per 100,000 persons have been constant over time, countries. Large (15- to 20-fold) geographic variations and corresponding age-standardized rates of deaths, in age-standardized stroke DALYs and mortality rates DALYs, and moderate (4-fold) geographic variations in age- mid-2000s standardized prevalence may be related to the varia- (Supplemental Figure 14B). The trends for the ab- tions in stroke risk factors or the quality of and/or solute access to preventative care, acute stroke care, and resemble those for high blood pressure. Taken stroke rehabilitation across the globe. Global and together, the increasing global prevalence and rates national health systems need to focus on new of HHD can be explained by population growth and and and YLLs and declined have steadily leveled age-standardized off until since estimates the then closely Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases F I G U R E 4 Map of Age-Standardized DALYs Due to Hypertensive Heart Disease in 2019 DALYs ¼ disability-adjusted life years. aging, but the declining age-standardized rates of because no such peaks are noted for high blood adverse outcomes are similar to those for IHD and pressure or other contributing factors, and it can stroke and are likely an effect of improved sec- represent regional differences in disease coding, ondary prevention. including that of peripartum cardiomyopathy. In- The age distributions of DALYs due to HHD are equalities in access to both primary and secondary very similar in women and men until age 70 years prevention are a potential cause of these regional (Supplemental Figure 15). This contrasts to the age and sex differences. distributions for high blood pressure, in which men The global prevalence of HHD and absolute rates of are overrepresented at younger ages. The similarities adverse outcomes are expected to continue to rise by sex in DALYs calls for an equal attention to the due to population growth and aging. The age- clinical prevention and treatment of HHD in women standardized rates of adverse outcomes due to HHD and men. are no longer decreasing, and with continuing global The highest age-standardized rates of DALYs due increases in obesity and diabetes, corresponding in- to HHD are noted in Africa (Figure 4). DALYs due to creases in left ventricular hypertrophy and other as- HHD are particularly higher in Central sub-Saharan pects of HHD are likely. Intensified global and Africa, followed by most of Africa except Western regional efforts to lower blood pressure and control sub-Saharan similar other risk factors are needed, for example with geographic pattern exists for high blood pressure Africa, population-wide reductions in dietary sodium intake. (with the exception of high rates of DALYs in men Continued surveillance of inequalities in adverse from high blood pressure in Central Asia and outcomes due to high blood pressure are necessary to Eastern Europe). An overrepresentation of DALYs inform such efforts. due to HHD in women can be noted in Central and CONGENITAL HEART ANOMALIES. A total of 3.12 Eastern (Supplemental million (95% UI: 2.40 to 4.11 million) babies were born Figure 16). The significance of this is uncertain with congenital heart anomalies (CHA) in 2019, sub-Saharan and Oceania. Africa A 2991 2992 Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases representing 2,305.2 per 100,000 live births (95% UI: The very young age distribution in LMICs and large 1,772.9 to 3,039.2 per 100,000 live births), a total of burden of YLLs due to CHA should drive a global 13.3 million (95% UI: 11.5 to 15.4 million) people were mandate for investment in data collection and re- living with CHA, and CHA was the underlying cause sources to expand access to infant heart surgery in of 217,000 deaths (95% UI: 177,000 to 262,000 regions in most need. In low-income countries with deaths), of which 150,000 deaths (95% UI: 120,000 to very young populations, the prevalence and mortality 184,000 deaths) were in infants <1 year (Figure 5A). from RHD parallel lack of access to cardiac surgery The all-ages rates of DALYs, YLLs, and YLDs for CHA services for CHA, and pooling resources to care for in 2019 were 241.6 per 100,000 (95% UI: 196.1 to 292.7 both of these diseases makes a stronger case for in- per 100,000), 234.0 per 100,000 (95% UI: 189.8 to vestment in surgical services (that includes both in- 285.7 per 100,000), and 7.6 per 100,000 (95% UI: 3.7 country surgical personnel and nongovernmental or- to 12.7 per 100,000), respectively (Figure 5B). ganizations) than for either disease alone. Between 1990 and 2019, the global CHA birth rate RHEUMATIC HEART DISEASE. The prevalence of was largely unchanged, but the all-ages death rate RHD has been rising steadily since 1990, reaching due to CHA declined 60.4% (95% UI: –71.9% to 40.5 million (95% UI: 32.1 to 50.1 million) currently –41.4%) from 7.1 per 100,000 (95% UI: 5.0 to 10.5 per affected in 2019 (Supplemental Figure 17A). Deaths 100,000) in 1990 to 2.8 per 100,000 (95% UI: 2.3 to 3.4 decreased until 2012 but have stabilized since then per 100,000) in 2019. Age-standardized prevalence, and even started increasing since 2017 (306,000 [95% death, and DALY rates remain lower than all-ages UI: 259,000 to 340,000] in 2019). DALYs and YLLs rates in low-income countries because of younger have slowly decreased to 10.7 million (95% UI: 9.21 to populations, higher birth rates of CHA, and much less 12.1 million) and 8.68 million (95% UI: 7.43 to 9.77 access to the intervention that is needed to allow for million), respectively, in 2019, whereas YLDs have the survival of children born with CHA. increased The proportion of all infant deaths caused by CHA to 1.99 million (95% UI: 1.20 to 3.04 million). increased in all quintiles of the sociodemographic Age-standardized rates for RHD prevalence have index (SDI) since 1990 except the highest because closely tracked with all-age rates, but age-standard- improvement in CHA mortality has lagged behind ized mortality has exceeded all-age mortality until the that of other causes, most notably infectious, respi- past few years, highlighting the differential mortality ratory, and diarrheal diseases (16). In low-SDI regions, risk due to RHD observed in regions with differing age CHA death rates have declined by 42.1% (95% UI: structures and levels of development (Supplemental –61.9% to 12.1%) since 1990, compared with declines Figure 17B). The narrowing of this differential tells a of 71.3% (95% UI: –74.7% to –64.6%) in high-SDI positive story about RHD care, although the domi- subgroups. has nance of China and India in the overall figures may limited ability to reduce the burden of CHA after mask persistent differentials in other high-prevalence birth; improvements in early diagnosis and access to countries and regions. The continuing increase in cardiac surgery are the only solutions. prevalence cannot be attributed to changes in age Unlike other CVDs, prevention The total number of global CHA births remained structure but likely reflects increased global aware- steady, global CHA deaths decreased by 42.7% (95% ness, the increasing availability of echocardiography UI: –59.3% to –15.2%), and the global number of for case definition, improved survival in some places, individuals living with CHA increased by 28.2% and the chronic nature of RHD. (95% UI: 26.3% to 30.1%). There were increases in Globally, the prevalence of RHD is estimated to the 15- to 49-year and the 50- to 69-year age peak between 20 and 29 years, remain relatively sta- groups, in which the number of individuals living ble until 40 years, and then begin a steady decline, with CHA grew by 41.6% (95% UI: 40.0% to 43.2%) likely reflecting decreasing survival at older ages. Sex and 117.3% (95% UI: 114.7% to 120.0%) to 4.21 distribution is equal until the age of 15 years, after million (95% UI: 3.67 to 4.76 million) and 1.31 which women bear a higher burden in terms of million (95% UI: 1.13 to 1.51 million), respectively, prevalence across nearly all world regions. Higher reflecting a cohort effect from the time of birth. rates of RHD in post-pubertal females are well Most of the prevalence increase occurred outside of described, but incompletely understood, and may high-income countries (HICs) and was due to im- reflect the interaction of biological, social, and envi- provements in survival and population growth. ronmental risk factors. Health systems will be increasingly burdened with adolescents and adults needing congenital heart conditions. care for their RHD burden continues to show substantial global heterogeneity (Supplemental Figure 18). The highest age-standardized DALY rates are seen in Oceania and Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases F I G U R E 5 Total Numbers and Rates of Congenital Heart Anomalies A B DALYs DALYs per 100,000 1,000 50,000 40,000 30,000 20,000 10,000 0 750 500 250 0 1990 2000 2010 1990 2019 2000 2010 2019 Deaths per 100,000 Deaths 12 600 9 400 6 200 3 0 0 2000 2010 Prevalence 15,000 10,000 5,000 0 1990 2000 2010 1990 2019 2019 Rate per 100,000 Persons Number (in Thousands) 1990 2000 2010 2019 Prevalent cases per 100,000 250 200 150 100 50 0 1990 2000 2010 2019 YLDs per 100,000 YLDs 1,000 16 750 12 500 8 250 4 0 0 1990 2000 2010 1990 2019 YLLs 2000 2010 2019 YLLs per 100,000 1,000 50,000 40,000 30,000 20,000 10,000 0 750 500 250 0 1990 2000 2010 Year 2019 Age-Standardized 1990 All Ages 2000 2010 Year 2019 <1 Year (A) Total number and number among children younger than 1 year of DALYs, deaths, prevalent cases, YLDs, and YLLs due to congenital heart anomalies, 1990 to 2019. Shaded regions represent 95% uncertainty intervals. (B) Age-standardized and all-ages DALY, death, prevalence, YLD, and YLL rates of congenital heart anomalies, 1990 to 2019. Shaded regions represent 95% uncertainty intervals. Abbreviations as in Figure 1. 2993 2994 Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases F I G U R E 6 Map of Age-Standardized DALYs Due to Rheumatic Heart Disease in 2019 DALYs ¼ disability-adjusted life years. South Asia (627.4 per 100,000 [95% UI: 404.1 to 918.0 The 2018 World Health Assembly Global RHD Reso- per 100,000] and 348.5 per 100,000 [95% UI: 272.4 to lution recommends to increase multisector invest- 412.2 per 100,000], respectively) with the lowest in ment in primary health care, improve sanitation and the 100,000). housing, infrastructure, secure medication supply Furthermore, although some regions have shown chains, evidence-based RHD screening, prevention large declines between 1990 and 2019 (Eastern and and management, and tertiary capacity to care for Central Europe, East Asia, Central Latin America, patients at the severe end of the RHD spectrum. RHD high-income Asia Pacific, and North Africa and the burden could be greatly decreased with an effective Middle East), there are also regions with only modest group A streptococcal vaccine, with several promising improvements little candidates currently in development (17). Future data improvement has been seen (Oceania, South Asia, the collection is needed at subnational levels to identify Caribbean, and sub-Saharan Africa). There is also and monitor populations with ongoing high RHD substantial within-region national and subnational burdens. highest-income and regions regions (<25 per where very variability in RHD DALYs, some examples of which include substantially higher RHD DALYs in Guyana CARDIOMYOPATHY AND MYOCARDITIS. DALYs due and Haiti compared to the rest of Latin America to cardiomyopathy and myocarditis have increased and the Caribbean and the heterogeneity seen in from 7.06 million (95% UI: 6.30 to 8.63 million) to 9.14 the subnational data on RHD DALYs from India million (95% UI: 7.86 to 10.0 million) over the past 30 (Figure 6). years, a pattern that is also seen in the rise of deaths RHD burden is highest among the world’s most from 238,000 (95% UI: 212,000 to 257,000) to 340,000 disadvantaged populations. The most marginalized (95% and poorest populations regionally, nationally, and at Figure 19A). However, over the same period, the a of age-standardized rate of death has decreased from improvement and continue to die early from RHD. 8.0 per 100,000 (95% UI: 6.4 to 8.6 per 100,000) to 5.6 subnational level are not showing signs UI: 285,000 to 371,000) (Supplemental Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases per 100,000 (95% UI: 4.5 to 6.3 per 100,000) in men ranged from 5 to 46 DALYs per 100,000 in South Asia, and 5.8 per 100,000 (95% UI: 4.4 to 6.4 per 100,000) East Asia, Andean Latin America, high-income Asia to 3.3 per 100,000 (95% UI: 2.7 to 3.6 per 100,000) in Pacific, and Central Latin America to 96 to 147 per women. The age-standardized morbidity and mor- 100,000 in Oceania, the Caribbean, high-income tality for men and women in 2019 remains different, North America, and Western and Eastern sub- at 6.5 per 100,000 YLDs (95% UI: 4.3 to 9.3 per Saharan Africa to 230 to 271 per 100,000 in Central 100,000 YLDs) and 4.2 per 100,000 YLDs (95% UI: 2.8 Asia, Eastern Europe, and Southern and Central sub- to 6.0 per 100,000 YLDs) and 148.9 per 100,000 YLLs Saharan Africa. These regional variations may be (95% UI: 120.2 to 168.7 per 100,000 YLLs) and 71.4 explained by a higher prevalence of peripartum car- per 100,000 YLLs (95% UI: 61.0 to 79.9 per 100,000 diomyopathy in Africa, Chagas disease in Central and YLLs), respectively. South America, and alcohol-related cardiomyopathy The prevalence and related mortality of cardiomyopathy and myocarditis increase in parts of Central Europe and Russia (20). throughout Although the morbidity and mortality rates from adulthood in both sexes, with a larger proportion of cardiomyopathies and myocarditis collectively pre- cases in men than in women. When myocarditis alone sent a substantial global disease burden in 2019, the is considered, a similar trend was observed. Referring regional differences in the burden (Figure 7) suggest to 2019, in the age between 35 and 39 years, that public health interventions should be tailored to when myocarditis can commonly occur (18,19), the the specific etiologies of cardiomyopathy to lower rate of myocarditis is 6.1 per 100,000 (95% UI: 4.2 these rates in the future. to 8.7 per 100,000) in men and 4.4 per 100,000 (95% UI: 3.0 to 6.3 per 100,000) in women. Similar figures ALCOHOLIC CARDIOMYOPATHY. The global preva- can be found in the range of ages between 20 and 44 lence of alcoholic cardiomyopathy (AC) estimated by years. GBD 2019 was 708,000 cases (95% UI: 545,000 to The increased prevalence associated with aging is more pronounced (95% UI: 7.0 to 11.9 cases per 100,000) (Supplemental myocarditis. Approximately a 6-fold higher age- Figure 21A). Globally, AC was responsible for 71,700 related was deaths (95% UI: 60,200 to 82,000 deaths), 2.38 observed in men between 35 and 39 years (10.8 per million YLLs (95% UI: 2.00 to 2.73 million YLLs), and 100,000 [95% UI: 6.5 to 17.4 per 100,000]) versus 60,100 YLDs (95% UI: 38,500 to 88,300 YLDs). The those between 80 and 84 years (698.5 per 100,000 total number of DALYs due to AC was 2.44 million [95% UI: 429.6 to 1064.8 per 100,000]) compared with (95% UI: 2.05 to 2.78 million). After a rapid increase myocarditis in men of 35 to 39 years (6.1 per 100,000 from [95% UI: 4.2 to 8.7 per 100,00]) versus those of 80 to decreasing from 2005 to 2019. The global prevalence 84 years (63.0 per 100,000 [95% UI: 43.6 to 87.9 per and YLDs due to AC are increasing. of cardiomyopathies other than 924,000 cases), approximately 9.1 cases per 100,000 in increase in cardiomyopathy 1999, DALYs, deaths, and YLLs started 100,000]). The relatively greater rise of other cardio- All-age and age-standardized rates of DALYs, myopathy compared to myocarditis prevalence with deaths, prevalent cases, YLDs, and YLLs declined age is constant, from 1990 to 2019. from 2005 to 2019 (Supplemental Figure 21B). This Myocarditis-related mortality rate between 35 indicates that the global increase in AC prevalence is and 39 years was 0.2 per 100,000 (95% UI: 0.2 to related, in part, to population growth and aging. 0.3 per 100,000) in men compared to 0.1 per Several countries in East Asia and the Caribbean re- 100,000 (95% UI: 0.1 to 0.2 per 100,000) in women gions in 2019. Alternatively, myocarditis resulted in death age-standardized values for almost all indicators. in 1 in 72 men (585 deaths per 42,200 incident Factors that might explain these regional differences cases) and 1 in 87 (324 deaths per 28,100 incident remain incompletely understood. showed opposite trends, with increasing cases) women in this age bracket who were diag- At the global level, substantially more total DALYs nosed in 2019. Between ages 80 and 84 years, the due to AC were experienced by men than women. rate was higher, at 1 death for every 19 incident DALYs from AC rose rapidly among men beginning cases of myocarditis in men (1,800 deaths per from age 25 years, being significantly higher in men 34,400 incident cases) and 1 death for every than 15 incident cases of myocarditis in women (2,260 Figure 22). Women are generally considered more deaths per 34,900 incident cases). susceptible to alcohol-induced damages than men, women across all ages (Supplemental Marked regional variations in other cardiomyopa- which may reflect sex-specific differences in alcohol thy in age-standardized DALYs in both sexes were consumption, type, blood level, distribution, or observed in 2019 (Supplemental Figure 20). These metabolism. However, the higher level of alcohol 2995 2996 Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases F I G U R E 7 Map of Age-Standardized DALYs Due to Cardiomyopathy and Myocarditis in 2019 DALYs ¼ disability-adjusted life years. consumption and the higher frequency of alcohol emphasis on eliminating alcohol use among people problems among men could justify the observed with co-existing CVD is advisable. A deeper under- higher rate of DALYs. standing of the exact mechanisms of disease, sus- Age-standardized DALYs due to AC were higher in ceptibility to alcohol damage, effective public health Central Europe as well as in the Caribbean (Cuba), interventions and treatments for AC, can optimize followed by Australasia, North America, Central Asia, preventive measures. Western America AF AND AFL. The total number of DALYs due to AF (Figure 8). Extremely high rates were seen in Eastern and AFL increased progressively from 3.79 million Europe, particularly in Russia and Kyrgyzstan. The (95% UI: 2.96 to 4.83 million) in 1990 to 8.39 million lowest levels were observed in sub-Saharan Africa, (95% UI: 6.69 to 10.5 million) in 2019 (Supplemental Andean Latin America, and North Africa and the Figure 23A). GBD 2019 estimated 59.7 million (95% Middle East. Geographic differences reflect drinking UI: 45.7 to 75.3 million) prevalent cases of AF/AFL in patterns among regions, for example, rates of binge 2019, about a doubling compared to the prevalent drinking, as well as social and cultural behaviors, cases in 1990. Europe, and tropical Latin such as abstaining from alcohol. When standardized for age, prevalence of AF/AFL, AC represents substantial morbidity and mortality DALYS, and death rates did not display marked among young and middle-age people, particularly changes between 1990 and 2019 (Supplemental men. The age-standardized DALYs are high in several Figure 23B). The age-standardized AF/AFL preva- countries, and the true burden of disease could be lence rate was 775.9 per 100,000 (95% UI: 592.4 to underestimated because alcohol consumption is 990.8 per 100,000) in 1990 and 743.5 per 100,000 often underreported (21). Additional support for (95% UI: 571.2 to 938.3 per 100,000) in 2019. Age- public education and awareness can help to reduce standardized rates for DALYs did not change sub- the harmful use of alcohol. Since alcohol negatively stantially between 1990, when they were 110.0 per impacts cardiovascular function, increased clinician 100,000 (95% UI: 87.7 to 139.2 per 100,000), to 2019, Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases F I G U R E 8 Map of Age-Standardized DALYs Due to Alcoholic Cardiomyopathy in 2019 DALYs ¼ disability-adjusted life years. when they were 107.1 per 100,000 (95% UI: 86.2 to the Caribbean, sub-Saharan Africa, and North Africa 133.7 per 100,000). Similarly, the age-standardized and the Middle East displayed low rates. However, death rates per 100,000 were similar in 1990 at 4.3 because of a general lack of data from these regions, per 100,000 (95% UI: 3.7 to 5.1 per 100,000) and 4.4 more detailed studies should be performed. The per 100,000 (95% UI: 3.7 to 5.0 per 100,000). reasons for this significant regional variation may Comparing total numbers with age-standardized include increased ascertainment in high-income numbers suggests that global increases in AF/AFL regions, differential control of risk factors, and ge- are largely attributable to aging of the population and netic factors. A detailed comparison of potential population growth. differentiating features between highest DALY rate Globally, under the age of 70 years, more total DALYs due to AF were experienced by men than versus lowest DALY rate regions could yield valuable additional information. women (Supplemental Figure 24). Between 70 and 74 AF/AFL are the most common arrhythmias and years, men and women had similar DALYs. However, continue to make a progressive and substantial at age 75 years and older, this trend was reversed, impact on public health at a global level. In most with by regions, prevalence rates are increasing, suggesting women. These trends were observed in 1990 as well that more effort is needed to improve prevention as 2019. These findings point toward sex-specific, and health care for AF/AFL at a global level. Health age-related targets for the prevention and manage- systems and countries will need to focus their ef- ment of AF/AFL. forts to reverse these trends by aggressive attention higher total DALYs experienced Age-standardized DALY rates due to AF/AFL were to the reduction of risk factors such as hyperten- highest in high-income North America, Australasia, sion, diabetes, and obesity; better treatment of in- Central Asia, and Europe and were observed to be dividuals with IHD and heart failure; and improved lowest access in the high-income Asia Pacific region (Figure 9). Also, Andean and Central Latin America, to prophylaxis. medications for thromboembolism 2997 2998 Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases F I G U R E 9 Map of Age-Standardized DALYs Due to Atrial Fibrillation and Flutter in 2019 DALYs ¼ disability-adjusted life years. AORTIC ANEURYSM. The total number of YLLs due rate in women has been shown to be more rapid, to aortic aneurysm, including both thoracic and rupture during surveillance 4 times more likely, and abdominal types, has increased steadily since 1990, likelihood of fatal rupture 3 times as high, even after reaching 3.32 million YLLs (95% UI: 3.11 to 3.52 million adjustment for age (22–24). For thoracic aortic aneu- YLLs) and 172,000 deaths (95% UI: 157,000 to 183,000 rysms, women have a lower incidence but are more deaths) in 2019 (Figure 10A). likely to have fatal consequences than men (25). Age-standardized rates for YLLs and deaths Age-standardized YLLs due to aortic aneurysm declined over this period, indicating that, overall, were highest in Eastern and Central Europe as well as global increases in aortic aneurysm have been due to Southern and Tropical Latin America, with extremely population growth and aging (Figure 10B). This likely high levels noted in Montenegro and parts of Brazil reflects improvement in diagnosis and treatment of (Supplemental Figure 26). The lowest levels were risk factors. observed in Andean Latin America, North Africa and At the global level, men bore a substantially higher the Middle East, and East Asia, including Mexico, burden of YLLs due to aortic aneurysm compared with Iraq, and China. Risk factors, including tobacco use women. YLLs from aortic aneurysm rose most steeply and hypertension, as well as access to screening and in the sixth decade of life for men, peaking by age 70 preventive health care, may partially explain these years (Supplemental Figure 25). Women younger than patterns. age 75 years accounted for less than one-half of YLLs Aortic aneurysm remains a major public health due to aortic aneurysm. The gap between men and issue, with the overall burden in terms of number of women narrowed with increasing age, with YLLs in YLLs and deaths increasing globally. Because age- women overtaking those of men at age 90 years. This standardized rates for YLLs and death due to aortic could be explained by the generally longer lifespan of aneurysm declined from 1990 to 2019, the increase women compared with men. Despite the lower preva- may be attributable to population growth and aging. lence of abdominal aortic aneurysm than men, growth However, because the risk factors for this disease Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases F I G U R E 1 0 Total Numbers and Rates of Aortic Aneurysm A B Deaths Deaths per 100,000 200 3 150 2 100 1 Rate per 100,000 Persons Number (in Thousands) 50 0 1990 2000 2010 2019 YLLs 3,000 0 1990 2000 2010 2019 YLLs per 100,000 60 40 2,000 20 1,000 0 0 1990 2000 2010 2019 2000 1990 Year 2010 2019 Year Age-Standardized All Ages (A) Total number of deaths and YLLs due to aortic aneurysm, 1990 to 2019. Shaded regions represent 95% uncertainty intervals. (B) Age-standardized and all-ages death and YLL rates of aortic aneurysm, 1990 to 2019. Shaded regions represent 95% uncertainty intervals. YLLs ¼ years of life lost. remain common, most national health systems will NONRHEUMATIC need to address increasing demand for preventive CALCIFIC AORTIC VALVE DISEASE. Calcific aortic VALVULAR HEART DISEASE: care, including low-cost screening modalities for valve disease (CAVD) occurs commonly among older abdominal aneurysms in the high-burden regions adults with a normal trileaflet aortic valve and with a mentioned earlier. The risk factors underlying the greater frequency among those with a congenital development of aortic aneurysm are common to bicuspid aortic valve. CAVD is clinically important other CVDs, such as IHD. As such, mitigating risk because severe obstruction causes symptoms and left factors through, for example, hypertension man- ventricular dysfunction warranting surgical or trans- agement and smoking cessation, could reduce the catheter valve replacement (26). The prevalence of burden of other diseases in addition to aortic CAVD increases with age and is >1,000 per 100,000 aneurysm. Combined with effective and accessible beyond the age of 75 years. screening technology, such as ultrasound, where Globally, both the prevalence and age- indicated, the morbidity and mortality due to standardized prevalence of CAVD have increased aortic aneurysm can be significantly decreased steadily over the last 3 decades (Supplemental globally. Figure 27B). In 2019, the age-standardized 2999 3000 Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases F I G U R E 1 1 Age-Standardized DALYs Due to Nonrheumatic Calcific Aortic Valve Disease in 2019 by Region DALYs per 100,000 Persons 60 40 20 ra l nt Ce Ce nt ra l As ia Eu Ea r st op er e n Eu H ig r op hAu H In e ig co st hr m a In l e a co sia As m ia e Pa So No ci ut rt fic he h Am rn La er ic tin a Am W e e An st r i ca er de n an Eu La ro tin pe Am er Ce ic nt Ca a ra r ib l La be Tr op tin No an ic rt Am al h La Af er ic tin ric a a Am an d er M ic a id dl e Ea st So ut h As ia Ea st As ia Ce O nt ce So ra a ut ni lS he a Ea ub as st t S er a A n ha sia So Su ra ut bn he A S fr ah rn ic ar W Su a an es b -S te A fr ah rn ic ar Su a an bAf Sa ric ha a ra n Af ric a 0 Female Male Age-standardized DALY rate of nonrheumatic calcific aortic valve disease by region and sex with 95% uncertainty intervals, 2019. DALYs ¼ disability-adjusted life years. prevalence rose to approximately 116.3 cases per prevalence among men exceeds that among women 100,000 (95% UI: 100.4 to 134.5 cases per 100,000) to varying degrees in the other regions of the world. people, from about 45.5 cases per 100,000 (95% UI: Population-based studies of the prevalence of non- 37.6 to 54.7 cases per 100,000) people in 1990. This rheumatic valvular heart disease remain rare, and increase may be attributable to increased prevalence further research is needed to understand if sex dif- of atherosclerotic risk factors associated with the ferences in prevalence are due to differences in dis- development and progression of CAVD (27). Although ease burden, health-seeking behavior, or rates of age-standardized YLDs due to CAVD have increased diagnosis. in parallel with prevalence, there has been no sig- There is substantial heterogeneity among coun- nificant change in age-standardized DALYs, most tries in age-standardized prevalence and DALYs due likely because most of the DALYs due to CAVD accrue to CAVD (Figure 11). Prevalence is low (<20 per from YLLs, whereas deaths due to CAVD (and conse- 100,000) in several regions of the world, notably, quently, age-standardized YLLs) have not increased sub-Saharan Africa (excluding the south), most of Asia over the years. The ready availability of aortic valve (including South and Southeast Asia), North Africa and replacement in regions of the world where CAVD is the Middle East, and Oceania. In contrast, age- most prevalent may be an important check on standardized prevalence is much higher (>200 per mortality. 100,000) in Australasia; high-income Asia Pacific and In HICs, the age-standardized prevalence of CAVD North America; and Central, Eastern, and Western is similar among both men and women, while the Europe. The difference may reflect higher prevalence Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases of other competing illnesses and lack of testing for DALYs due to MV disease than men, peaking at age 75 CAVD in LMICs. Despite the low prevalence of CAVD in to 79 years. Prior studies have found that women with LMICs, DALYs due to CAVD are disproportionately severe regurgitation have higher mortality and lower high, possibly reflecting the limited access to timely surgery rates than men, which may account for some aortic valve replacement (28). of the increased DALYs in older women (32). As populations age, CAVD becomes an increasingly Age-standardized DALYs due to MV disease were important cause of morbidity and mortality. The in- highest for both men and women in Central Europe; crease in reported prevalence of CAVD may be a specifically, high rates were seen in Serbia, Bosnia consequence of both an increase in the prevalence of and Herzegovina, and Hungary, with the lowest risk factors for atherosclerosis and an increased levels seen in Southeast Asia, East Asia, and Andean awareness and investigation to detect disease. Latin America (Supplemental Figure 29). Women had Although major advances have been made in the higher DALYs than men in most regions except Cen- treatment of end-stage CAVD, research on ways to tral Asia, Eastern Europe, Australasia, the Caribbean, prevent the onset and progression of disease requires and additional investments. In the populous regions of Figure 30). Western sub-Saharan Africa (Supplemental the world such as South Asia and Africa, despite the Degenerative MV disease continues to be a major low prevalence of CAVD, the absolute number of threat to public health, and the overall burden in people with CAVD is large. An improved health care terms of number of DALYs, deaths, and prevalent infrastructure and an augmented healthcare work- cases is increasing globally. Prevention of MV disease force could provide timely valve interventions for through reduction in risk factors remains a key public these patients and thereby reduce related morbidity health issue. In addition, given an aging population in and mortality. many regions, health systems should focus on improving access to diagnostic imaging (i.e., echo- NONRHEUMATIC VALVULAR HEART DISEASE: cardiography) and subspecialty care for close follow- DEGENERATIVE MITRAL VALVE DISEASE. The major up. Improved access to surgical and percutaneous cause of nonrheumatic degenerative mitral valve interventions is also needed to decrease mortality (MV) disease is MV prolapse (29,30). Untreated, this and long-term sequelae and improve quality of life for can lead to chronic mitral regurgitation, AF, and heart those with MV disease (33). failure (31). The total number of DALYs due to degenerative MV disease has increased since 1990 ENDOCARDITIS. The total number of DALYs due to and is responsible for 883,000 DALYs (95% UI: endocarditis has risen steadily since 1990, reaching 754,000 to 1,090,000 DALYs) and 34,200 deaths (95% 1.72 million (95% UI: 1.36 to 1.94 million) DALYs and UI: 28,300 to 43,300 deaths) in 2019 (Supplemental 66,300 deaths (95% UI: 46,200 to 75,900 deaths) in Figure 28A). GBD 2019 estimated 24.2 million (95% 2019 (Figure 13A). GBD 2019 estimated 1.09 million UI: 23.1 to 25.4 million) prevalent cases of degenera- (95% UI: 0.913 to 1.30 million) incident cases of tive MV disease in 2019. endocarditis in 2019. Age-standardized rates for DALYs, deaths, and Age-standardized rates show an increase in inci- prevalent cases of degenerative MV disease declined dence, from 9.9 per 100,000 (95% UI: 8.2 to 11.8 per over this time period, suggesting that the global in- 100,000) to 13.8 per 100,000 (95% UI: 11.6 to 16.3 per creases in MV disease have been due to population 100,000), as well as deaths, from 0.7 per 100,000 growth and aging (Supplemental Figure 28B). The (95% UI: 0.6 to 0.9 per 100,000) to 0.9 per 100,000 regions age- (95% UI: 0.6 to 1.0 per 100,000) (Figure 13B). Although standardized DALYs between 1990 and 2019 are there has been a slight increase in the DALYs, YLLs, high-income Asia Pacific, North Africa and the Middle and YLDs caused by endocarditis across all ages, once East, and Australasia. However, for some regions—for standardized for age structure and growth, these example, in Eastern Europe and Central Asia—age- metrics are largely static between 1990 and 2019. The standardized rates have not declined. increase in death may be explained by an increasing with the largest reductions in At the global level, substantially more total DALYs proportion of endocarditis caused by virulent organ- due to MV disease were experienced by women than isms such as staphylococci or complex infection in men. For almost all age groups, MV disease DALYs patients not fit for surgical intervention. were higher in women than men (Figure 12). Globally, At the global level, more total DALYs due to women and men had similar DALYs in the 40- to 44- endocarditis were experienced by men than women year age groups, but the levels diverged after age 65 in 2019 (973,000 DALYs [95% UI: 736,000 to 1,120,000 years, when women had more than one-third more DALYs] versus 751,000 DALYs [95% UI: 537,000 to 3001 Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases F I G U R E 1 2 DALYs Due to Nonrheumatic Degenerative Mitral Valve Disease in 2019 by Age 80 60 Number of DALYs (in Thousands) 40 20 us Pl 95 90 to to 94 89 84 85 80 to to 79 74 75 to to 69 70 60 65 to to 64 59 54 55 50 to to 49 44 45 to to 39 40 35 to 34 29 30 to 24 25 to 20 to 19 0 15 3002 Age Female Male Number of DALYs due to nonrheumatic degenerative mitral valve disease by age and sex with 95% uncertainty intervals, 2019. Ages younger than 15 years were removed from the figure because they are not modeled for this cause. DALYs ¼ disability-adjusted life years. 871,000 DALYs]). DALYs from endocarditis rose large part, areas with high age-standardized DALY rapidly for both sexes from birth and reached a peak rates for endocarditis mirror those areas with a high at age 55 to 59 years for men and age 65 to 69 years prevalence of RHD, for example, in Oceania, South- for women (Supplemental Figure 31). Women ages east Asia, and sub-Saharan Africa. 75 years and older had more DALYs due to endocarditis than men in the same age group. There is wide variation in the regional age- The epidemiology of endocarditis, including predisposing conditions, is heterogeneous. Therefore, it is not surprising that the endocarditis-associated YLDs endocarditis and DALYs vary considerably by location. Both the (Supplemental Figures 32 and 33). In 2019, the highest endocarditis-associated YLDs and DALYs increased in rates were seen in Oceania, with 44.9 DALYs per 76.2% and 52.4% of locations, respectively. Staphylo- 100,000 (95% UI: 30.7 to 60.7 DALYs per 100,000) coccus aureus has become the predominant endo- (across men and women), followed by Southern Latin carditis pathogen in many areas of the world and is America (40.1 DALYs per 100,000 [95% UI: 32.7 to extremely virulent and a well-recognized marker of 49.6 DALYs per 100,000]) and Southeast Asia (38.6 worse outcomes (34). As a result, mounting human and DALYs per 100,000 [95% UI: 31.6 to 53.8 DALYs per health care burdens mandate that an individualized 100,000]). There were also high rates in Eastern approach be developed for each location to better un- Europe (especially in men), the Caribbean, Tropical derstand the unique epidemiology of endocarditis so Latin America, and Africa. The lowest DALYs for that efforts can be focused on management and pre- endocarditis were seen in Central and East Asia. In vention of this life-threatening condition. standardized DALY rate due to Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases F I G U R E 1 3 Total Numbers and Rates of Endocarditis A B DALYs DALYs per 100,000 2,000 30 1,500 20 1,000 10 500 0 0 1990 2000 2010 2019 1990 Deaths 2010 2019 Deaths per 100,000 80 1.2 60 0.9 40 0.6 20 0.3 0 0.0 2000 2010 2019 Incidence 1,000 500 0 1990 2000 2010 2019 1990 Rate per 100,000 Persons 1990 Number (in Thousands) 2000 2000 2010 2019 New cases per 100,000 15 10 5 0 1990 YLDs 2000 2010 2019 YLDs per 100,000 50 0.8 40 0.6 30 0.4 20 0.2 10 0 0.0 1990 2000 2010 2019 1990 YLLs 2000 2010 2019 YLLs per 100,000 2,000 30 1,500 20 1,000 10 500 0 0 1990 2010 2000 Year 2019 Age-Standardized 1990 2000 2010 Year 2019 All Ages (A) Total number of DALYs, deaths, incident cases, YLDs, and YLLs due to endocarditis, 1990 to 2019. Shaded regions represent 95% uncertainty intervals. (B) Age-standardized and all-ages DALY, death, incidence, YLD, and YLL rates of endocarditis, 1990 to 2019. Shaded regions represent 95% uncertainty intervals. Abbreviations as in Figure 1. 3003 3004 Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases F I G U R E 1 4 Map of Age-Standardized DALYs Due to Peripheral Artery Disease in 2019 DALYs ¼ disability-adjusted life years. PERIPHERAL ARTERY DISEASE. The global numbers increased throughout the of prevalent cases and deaths due to PAD have risen Numbers and rates of cases were higher in women consistently each year since 1990, resulting in a 2-fold than men at all ages. Deaths and DALYs showed in- increase to 113 million cases (95% UI: 99.2 to 128 creases with age comparable to prevalence except million cases) and 74,100 deaths (95% UI: 41,200 to that deaths and DALYs were higher in men than 128,000 deaths) in 2019 (Supplemental Figure 34A). women up to very old age. whole age spectrum. Comparable trends in DALYs, YLLs, and YLDs have The numbers of prevalent cases increased in both resulted in 1.54 million (95% UI: 1.01 to 2.37 million), men and women at all ages by up to 2-fold since 1990, 1.04 million (95% UI: 0.604 to 1.78 million), and but age-standardized prevalence rates were slightly 501,000 (95% UI: 235,000 to 898,000) respec- lower in 2019 than in 1990. Numbers of deaths and tively in 2019. DALYs were higher in 2019 compared to 1990 in both In keeping with the increase in numbers of preva- men and women at all ages, but over the same period, lent cases, deaths, DALYS, YLLs, and YLDs, rates per age-standardized death rates remained much the 100,000 persons of all ages increased between 1990 same, and DALY rates fell slightly. and 2019 (Supplemental Figure 34B). The trends in Age-standardized DALY rates varied by world re- age-standardized rates of deaths and YLLs were flat gion in 2019 (Figure 14). Higher rates (>25 per 100,000 from 1990 to 2019, and prevalence, YLDs, and DALYs persons) were found in both men and women in declined slightly. Overall, the PAD prevalence in- Europe (western, central, and eastern), North Amer- crease reflects population growth rather than a major ica, Australasia, the Caribbean, and sub-Saharan Af- change in age-specific incidence. In both 1990 and rica (central, eastern, and southern) (Supplemental 2019, cross-sectional analyses show that the numbers Figure 35). Especially high rates occurred in men in of prevalent cases increased with age in both men and Eastern Europe and areas of sub-Saharan Africa. women up to 70 years of age and prevalence rates Lowest DALY rates were found in Asia, Andean Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases countries, West and North Africa and the Middle East. attributed to population growth and aging. However, The pattern was similar in men and women, with in some regions—for example, Oceania—the age- most regions showing higher rates in men, but in re- standardized rates of DALYs, deaths, YLDs, and gions with low overall rates, the sex differences were YLLs increased between 1990 and 2019. small. The burden of PAD is increasing not only in Globally, DALYs due to high SBP in 2019 were developed HICs but also in LMICs, where concomitant higher among men compared with women from ages risk 15 to 19 through 70 to 74 years, but higher among factors such as diabetes and obesity are increasing. women compared to men in those 80 to 84 years or Despite decreases in PAD age-standardized preva- older (Figure 15). Age-standardized DALYs were lence, deaths, DALYs, YLDs, and YLLs, overall rates higher among men compared with women in all re- have increased because of worldwide increases in life gions of the world (Supplemental Figure 37). expectancy. High DALY rates of PAD in Eastern In 2019, there was an approximately 8-fold varia- Europe and parts of Africa, particularly in men, tion require investigation. PAD is highly prevalent and is attributed to high SBP (Supplemental Figure 38). both underrecognized and inadequately studied. Rates of DALYs were lowest for both women and men across regions in age-standardized DALYs in the high-income Asia Pacific region and highest in MODIFIABLE RISK FACTORS Central Asia. Marked variation was also noted for rates of death, YLLs, and YLDs. The highest age- HIGH SYSTOLIC BLOOD PRESSURE. With aging of standardized rates of death and YLLs were noted in the population and population growth, the number of Central Asia and Eastern Europe among men and adults worldwide affected by high systolic blood in Central Asia, North Africa and the Middle East, and pressure (SBP) increased from 2.18 billion (95% UI: Central sub-Saharan Africa among women. The 95% UI: 2.11 to 2.26 billion) to 4.06 billion (95% UI: highest rate of YLDs was noted in Central Asia, Cen- 3.96 to 4.15 billion) from 1990 to 2019 (Supplemental tral Europe, and Southeast Asia for men and in North Table 1). High SBP is defined by GBD 2019 according Africa and the Middle East, East Asia, and Southeast to Asia for women. a theoretical minimum risk exposure level (TMREL) of $110 to 115 mm Hg, which is the level of High SBP is a major public health challenge, exposure that minimizes risk at the population level. affecting approximately 9 of 10 adults worldwide, In 2019, there were 828 million (95% UI: 768 to 888 and is associated with high rates of DALYs, death, million) adults with SBP >140 mm Hg, a common YLDs, and YLLs. High SBP and its adverse health threshold for treatment with pharmacotherapies. The consequences can be prevented by eating a heart- prevalence of adults worldwide with high SBP healthy diet that includes <1 teaspoon of salt per increased from 84,481.1 per 100,000 persons (95% UI: day and adequate potassium from fruits and vege- 81,641.5 to 87,579.2 per 100,000 persons) in 1990 to tables, maintaining a normal weight, increasing 88,971.1 per 100,000 persons (95% UI: 86,950.0 to physical activity, and avoiding unhealthy alcohol 91,028.8 per 100,000 persons) in 2019. intake (35). From 1990 to 2019, the total number of DALYs due HIGH FASTING PLASMA GLUCOSE. There are large to high SBP increased from 154 million (95% UI: 139 to differences between and within countries in the 169 million) to 235 million (95% UI: 211 to 261 million) burden of high fasting plasma glucose, defined as (Supplemental Figure 36A). Additionally, between above the TMREL of 4.8 to 5.4 mmol/l. The findings 1990 and 2019, the number of deaths (6.79 million showed [95% UI: 6.07 to 7.50 million] to 10.8 million [95% UI: mortality rates from high fasting plasma glucose and 9.51 to 12.1 million]), YLDs (10.1 million [95% UI: 7.30 significant increases in age-standardized YLDs be- to 13.1 million] to 21.2 million [95% UI: 15.2 to 27.2 tween 1990 and 2019. Age-standardized mortality due million]), and YLLs (144 million [95% UI: 129 to 158 to high fasting plasma glucose actually increased million] to 214 million [95% UI: 191 to 237 million]) from 1990 to 2005, with a downward trend thereafter. attributed to high age-standardized Between 1990 and 2019, a total of 134 million (95% UI: 107 to 171 million) deaths due to high fasting attributed to high SBP declined from 1990 to 2019, plasma glucose were recorded globally. The number whereas the age-standardized rate of YLDs did not of deaths increased from 2.91 million (95% UI: 2.34 to change 3.75 million) in 1990 to 6.50 million (95% UI: 5.11 to this The in standardized rates of DALYs, deaths, and YLLs over increased. improvement age- substantially SBP little time period (Supplemental Figure 36B). These data indicate that 8.36 the increases in total number of disease events can be standardized mortality rate due to high fasting million) in 2019 (Figure 16A). The age- 3005 Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases F I G U R E 1 5 DALYs Due to High Systolic Blood Pressure in 2019 by Age 20 15 Number of DALYs (in Millions) 10 5 us Pl 94 to 90 to 95 89 84 85 to 80 to 79 74 75 to 69 70 to 65 to 60 55 to 64 59 54 to 50 to 45 to 49 44 39 40 35 to to 34 29 30 to 24 25 to 20 to 19 0 15 3006 Age Female Male Number of DALYs due to high systolic blood pressure by age and sex with 95% uncertainty intervals, 2019. Ages younger than 15 years were removed from the figure because they are not modeled for this risk. DALYs ¼ disability-adjusted life years. plasma glucose increased between 1990 and 2005 Age-standardized DALYs due to high fasting from 84.2 per 100,000 deaths (95% UI: 65.9 to 111.1 plasma glucose were higher in Oceania, followed by per 100,000 deaths) to 89.2 per 100,000 deaths (95% Central Asia (Supplemental Figure 40). There were UI: 70.2 to 115.9 per 100,000 deaths) then declined large variations between countries in high fasting to 83.0 per 100,000 deaths (95% UI: 64.5 to 107.1 per plasma glucose DALY burden, with notably high rates 100,000 in Uzbekistan, Afghanistan, Papua New Guinea, deaths) in 2019 (Figure 16B). Age- standardized DALYs followed the same patterns Egypt, and Oman (Supplemental Figure 41). The with a peak in 2005 and then a decline until 2019. In highest contrast, age-standardized DALY rates were higher in observed in Kiribati at 12,255.2 per 100,000 (95% UI: 2019 at 2,104.3 per 100,000 (95% UI: 1,740.7 to 2,520.7 9,799.7 to 15,073.0 per 100,000), and the highest age- per 100,000) than in 1990 at 1,959.6 per 100,000 (95% standardized death rates were also observed in UI: 1,638.7 to 2,362.4 per 100,000). Of course, this is Kiribati at 435.4 per 100,000 (95% UI: 347.0 to 540.5 the result of a sharp increase in age-standardized per 100,000). Large variations were also observed YLDs from 1990 to 2019. Men had higher DALY within countries. For example, the age-standardized age-standardized DALYs in 2019 were burden than women throughout the study period DALY rate varied in Brazil from 1,571.8 per 100,000 until the age of 80 years, after which women had a (95% UI: 1,293.6 to 1,909.1 per 100,000) in Minas higher number of DALYs (Supplemental Figure 39). Gerais to 3,286.5 per 100,000 (95% UI: 2,735.5 to DALYs due to high fasting plasma glucose increased 3,907.3 per 100,000) in Alagoas, a 70.6% difference in with age, peaked at 70 years, and then declined. the country. Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases F I G U R E 1 6 Total Numbers and Rates of High Fasting Plasma Glucose A B DALYs DALYs per 100,000 3,000 200 150 2,000 100 1,000 50 0 0 1990 2000 2010 2019 1990 Deaths 2000 2010 2019 Deaths per 100,000 7.5 100 2.5 0.0 1990 2010 2000 2019 YLDs 60 40 Rate per 100,000 Persons Number (in Millions) 5.0 50 0 1990 2000 2010 2019 YLDs per 100,000 750 500 20 250 0 0 1990 2010 2000 1990 2019 YLLs 2000 2010 2019 YLLs per 100,000 150 2,000 100 1,500 1,000 50 500 0 0 1990 2000 2010 2019 1990 Year 2000 2010 2019 Year Age-Standardized All Ages (A) Total number of DALYs, deaths, YLDs, and YLLs due to high fasting plasma glucose, 1990 to 2019. Shaded regions represent 95% uncertainty intervals. (B) Age-standardized and all-ages DALY, death, YLD, and YLL rates of high fasting plasma glucose, 1990 to 2019. Shaded regions represent 95% uncertainty intervals. Abbreviations as in Figure 1. 3007 3008 Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases plasma Age-standardized DALYs due to high LDL choles- glucose level help track the global rise in diabetes. terol were highest in Eastern Europe, North Africa GBD 2019 showed low rates of physical activity (LPA) and the Middle East, Oceania, and Central Asia These population-based estimates of and poor diet in many countries. Both are major risk (Supplemental Figure 44). The lowest levels are pre- factors for high fasting plasma glucose and have led sent in high-income Asia Pacific, Australasia, Western to caloric imbalance and higher rates of obesity, Europe, and Andean Latin America and, by country, which has rapidly increased globally since 1990 and in the Republic of Korea, Japan, Rwanda, France, affects most geographic areas. There is a need to Israel, and Spain (Figure 17). Potential explanations develop and implement both public health policies for these differences in regional patterns include the and clinical programs to reduce health disparities and correspondingly LPA, increased high body mass index disease burden due to diabetes. (BMI), dietary patterns, and increased tobacco use in HIGH LOW-DENSITY LIPOPROTEIN CHOLESTEROL. the same regions and countries. The total number of DALYs due to high low-density High LDL cholesterol remains a major threat to lipoprotein (LDL) cholesterol, defined by a TMREL public health, and the overall burden in terms of of 0.7 to 1.3 mmol/l, has risen steadily since 1990, number of DALYs, deaths, YLDs, and YLLs is reaching 98.6 million (95% UI: 80.3 to 119 million) increasing globally. In some locations, the risk DALYs and 4.40 million (95% UI: 3.30 to 5.65 million) associated with high LDL cholesterol is especially deaths in 2019 (Supplemental Figure 42A). Over the high and deserves immediate public health atten- same period, the YLDs and YLLs rose to 5.71 million tion. Health systems and countries may need to (95% UI: 3.68 to 8.27 million) and 92.9 million (95% focus on new approaches that can reverse these UI: 75.6 to 111 million), respectively. This indicates trends. These might include improved government that the direction of the global trend for high LDL policies on diet and tobacco, school physical activity is increasing. programs, and, when needed, the use of lipid- Over the study period, the global all-age rates for lowering therapy in keeping with contemporary DALYs, deaths, and YLLs remained relatively static guidelines in which statins are the first choice. More and increased for YLDs (Supplemental Figure 42B). global During this time, the age-standardized rates for the cholesterol–related knowledge and therapeutic gaps same measures all declined. This difference between is needed to address this persistent global health all-age rates and age-standardized rates suggests that threat. investment in research to address LDL although the global burden of LDL-related disease HIGH BMI. Obesity, defined by elevated BMI ($30 kg/ remains unacceptably high, on average, the observed m 2), has reached epidemic levels worldwide. Elevated increases in the burden of DALYs in locations like BMI worsens most of the CVD risk factors, including China and India have been driven primarily by pop- adverse effects on blood pressure, blood sugar, lipids, ulation growth and aging. This trend is important for and inflammation and has adverse effects on cardiac global health because it implies that there has been at structure and function. Not surprisingly, hyperten- least modest progress in reducing the burden of LDL- sion, coronary heart disease, heart failure, and AF are related disease globally. Age-standardized DALY rates increased with obesity (36). attributable to elevated LDL cholesterol, however, are estimated to be increasing in some locations, including Pakistan and Saudi Arabia. Globally, 5.02 million (95% UI: 3.22 to 7.11 million) deaths and 160 million (95% UI: 106 to 219 million) DALYs were attributed to high BMI in 2019 At the global level, significantly more total DALYs (Figure 18A). High BMI, defined as above a TMREL of from elevated LDL were experienced by men than 20 to 25 kg/m 2 for adults and above normal weight for women. LDL-related DALYs increased rapidly for men children, contributed to more YLLs (119 million [95% beginning at age 30 years (Supplemental Figure 43). UI: 79.6 to 164 million]) than YLDs (40.9 million [95% Men ages 40 to 44 years had as many DALYs due to UI: 24.5 to 60.9 million]) in 2019. Globally, between LDL as women ages 60 to 64 and 80 to 84 years and 1990 and 2019, the absolute numbers of deaths more than women in all other age groups. In aging attributable to high BMI increased (2.20 million [95% post-menopausal women, the LDL cholesterol levels UI: 1.21 to 3.43 million] to 5.02 million [95% UI: 3.22 to are comparable to those of men of similar age. The 7.11 million]), as did DALYs (67.3 million [95% UI: 38.0 difference in DALYs by sex and age suggests that the to 104 million] to 160 million [95% UI: 106 to 219 burden of premature LDL-related disease in men million]), YLDs (12.9 million [95% UI: 6.9 to 21.0 younger than 65 years may need focused public million] health attention. 60.9 million]), and YLLs (54.4 million [95% UI: 30.2 to to 40.9 million [95% UI: 24.5 to Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases F I G U R E 1 7 Map of Age-Standardized DALYs Due to High LDL Cholesterol in 2019 DALYs ¼ disability-adjusted life years; LDL ¼ low-density lipoprotein. 84.4 million] to 119 million [95% UI: 79.6 to 164 million]). Age-standardized DALY rates due to high BMI are highest in Oceania, Central Asia, North Africa and the After standardization for population growth and Middle East, Southern sub-Saharan Africa, Eastern aging, rates of deaths attributable to high BMI have Europe, Central Latin America, the Caribbean, and increased only modestly from 1990 to 2019 (4.9% in- Central Europe (Supplemental Figure 46). Among crease [95% UI: –7.3% to 24.6%]), DALYs (18.0% [95% countries, Japan has the lowest and Kiribati the UI: 2.2% to 42.3%]), and YLLs (8.3% [95% UI: –6.6% to highest 31.2%]), suggesting that population growth and aging (Supplemental Figure 47). The global findings are of the population have contributed substantially to generally similar between men and women in most the global trends in obesity-associated burden of regions, but age-standardized DALYs are notably disease (Figure 18B). YLDs have increased more higher for men in Central Asia and Central and sharply (60.2% [95% UI: 41.3% to 90.2%]) from 1990 Eastern Europe. age-standardized DALYs in the world to 2019. Since population growth and aging from 1990 Great efforts are needed to promote the prevention account for much of the absolute increases attribut- of obesity and its progression to more severe forms able to high BMI, the focus may need to be on stra- (36). A multifactorial approach is required to promote tegies targeting prevention of weight gain at younger improving dietary quality, especially reductions in ages to decrease the burden of all measures, including simple sugars, complex carbohydrates, and total cal- YLDs. ories. Community prevention programs, like the Global DALYs attributable to high BMI are highest Diabetes Prevention Program, duplicated in many between ages 45 and 75 years and are slightly higher programs (37), are needed (36). Optimizing efforts to for men at younger and middle ages and for women at promote physical activity and exercise training are older ages (Supplemental Figure 45). needed, as well as reductions in sedentary behavior 3009 Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases F I G U R E 1 8 Total Numbers and Rates of High Body Mass Index A B DALYs DALYs per 100,000 3,000 200 150 2,000 100 1,000 50 0 0 1990 2000 2010 2019 1990 Deaths 6 90 4 60 2 0 1990 2000 2000 2010 2019 Deaths per 100,000 2010 2019 YLDs 60 40 Rate per 100,000 Persons Number (in Millions) 3010 30 0 1990 2000 2010 2019 YLDs per 100,000 750 500 20 250 0 0 1990 2000 2010 2019 1990 YLLs 2000 2010 2019 YLLs per 100,000 2,500 150 2,000 100 1,500 1,000 50 500 0 0 1990 2000 2010 2019 1990 Age-Standardized All Ages Year 2000 2010 2019 Year (A) Total number of DALYs, deaths, YLDs, and YLLs due to high body mass index, 1990 to 2019. Shaded regions represent 95% uncertainty intervals. (B) Age-standardized and all-ages DALY, death, YLD, and YLL rates of high body mass index, 1990 to 2019. Shaded regions represent 95% uncertainty intervals. Abbreviations as in Figure 1. Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 and making neighborhoods, Global Burden of Cardiovascular Diseases and (Figure 19). Men in Central Latin America have among workplaces more suitable to allow for these healthier communities, the highest age-standardized DALYs at 2,091.2 per lifestyle behaviors. Potential governmental involve- 100,000 people (95% UI: 1,791.6 to 2,424.8 per ment, such as mandating caloric/nutrition menu la- 100,000 people), double the global rate and 60% beling and regulation of food ingredients, as well as higher than in 1990 (Supplemental Figure 52), which controlling advertisements and certain forms of represents an epidemic of CKD of unknown origin beverage and food item taxation, etc., could be that appears to be common in coastal lowlands, with instituted. Governmental intervention was very suc- repeated heat stress, pesticide, and heavy metal cessful decades ago in the North Karelia Project in exposure implicated as potential causes (39). Finland (36,38), and potentially, similar efforts could CKD is emerging as a growing global problem, with be successful for obesity intervention worldwide. marked growth related to the aging population. Age- Research is needed to identify effective methods of standardized DALYs for IKF have declined by only health promotion that will reduce obesity and align 7.7%, compared to 39.3% for all risk factors, and they all allied health professions toward this important increased in Central and Andean Latin America, the goal (36). Caribbean, Central and Southeast Asia, Oceania, and Southern sub-Saharan Africa. Much of CKD remains IMPAIRED KIDNEY FUNCTION. GBD 2019 estimates undiagnosed and undertreated. Governments, health use the term chronic kidney disease (CKD) to refer to systems, physicians, and patient attention are needed the morbidity and mortality that can be directly to improve the diagnosis of CKD by measuring pro- attributed to all stages of CKD and the term impaired teinuria and estimated glomerular filtration rate. kidney function (IKF) to capture the additional risk of There is also a need for earlier markers of kidney CKD from other associated conditions such as CVD injury. Diabetes and hypertension are leading factors and gout. The DALYs due to IKF nearly doubled from for 1990 to 2019, reaching 76.5 million (95% UI: 67.8 to Improving their prevention and control will reduce 86.3 million) DALYs and 3.16 million (95% UI: 2.72 to the burden of CKD. Therapeutic options for CKD are CKD, its progression, and associated risk. 3.62 million) deaths globally in 2019 (Supplemental increasing Figure 48A). The estimated global prevalence of angiotensin system blockade in proteinuria and CKD is 9,011.9 per 100,000 (95% UI: 8,401.3 to 9,577.8 possibly sodium-glucose cotransporter-2 inhibitors per 100,000) (697 million [95% UI: 650 to 741 million] and mineralocorticoid receptor antagonists. Trials are people), 41.1% (95% UI: 38.9% to 43.4%) higher than underway to test prevention of kidney events in pa- in 1990 due to aging (Supplemental Figures 49A tients with CKD without diabetes. A combination of and 49B). population-based Age-standardized DALYs due to IKF declined increased with CKD the proven public benefits health recognition and of renin- measures for awareness and slightly from 1,024.1 DALYs per 100,000 people (95% improved therapies to reduce risk is needed to reduce UI: 898.4 to 1,154.8 DALYs per 100,000 people) to the burden of CKD. 945.3 DALYs per 100,000 people (95% UI: 836.3 to 1,066.8 DALYs per 100,000 people) from 1990 to 2019 AMBIENT AND HOUSEHOLD AIR POLLUTION. Air (Supplemental Figure 48B). This 7.7% (95% UI: –12.9% pollution is the leading environmental risk factor for to –2.4%) decline in DALYs lags behind the 39.3% global health and the fourth largest risk factor for (95% UI: –43.5% to –34.9%) decline in DALYs for all global mortality. Two main forms of air pollution risk factors combined. The age-standardized rate per quantified in GBD 2019 contribute substantially to the 100,000 people for YLDs from IKF increased from burden of CVD: ambient particulate matter with an 115.9 (95% UI: 84.7 to 150.5) to 139.4 (95% UI: 101.8 to aerodynamic diameter smaller than 2.5 m m (PM2.5) 181.8) from 1990 to 2019. Growth and aging of the and household air pollution (HAP) from the use of global population resulted in an increase in all un- solid fuels for cooking. In 2019, CVD accounted for adjusted disease burden measures for IKF. 51.5% and 30.5% of the total DALYS attributable to CKD and its consequences generally rise markedly PM2.5 and HAP, respectively. with age and are higher among men than women, but Despite substantial reductions in ambient PM 2.5 trends over time were similar across age and sex concentrations in North America and Europe, levels groups (Supplemental Figures 50 and 51). remain high throughout most of the world (40). Geographically, the highest age-standardized rates Global annual average population-weighted PM2.5 of DALYs due to IKF are now seen in Central Latin levels increased slightly from 40.8 mg/m 3 in 1990 to America, Central Asia, the Caribbean, North Africa 42.6 m g/m 3 in 2019. However, the global disease and the Middle East, Oceania, and Southeast Asia burden attributable to ambient PM 2.5 increased from 3011 3012 Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases F I G U R E 1 9 Map of Age-Standardized DALYs Due to Impaired Kidney Function in 2019 DALYs ¼ disability-adjusted life years. 70.5 million (95% UI: 47.3 to 98.9 million) DALYs and attributable to HAP have also declined sharply, 2.05 million (95% UI: 1.45 to 2.74 million) deaths in indicating the impact of 1990 to 118 million (95% UI: 95.9 to 138 million) (Supplemental Figure 54B). DALYs and 4.14 million (95% UI: 3.45 to 4.80 million) standardized rates of DALYs attributable to HAP deaths, remain high throughout much of sub-Saharan Africa, respectively, in 2019 (Supplemental exposure reduction However, age- Figure 53A). Age-standardized rates for DALYs and which deaths attributable to PM 2.5 have remained relatively improved access to clean household energy sources constant between 1990 and 2019, indicating that, on seen in India, China, and much of Southeast Asia average, global increases in attributable disease have (Supplemental Figure 55). The highest rates of been due to population growth and aging, especially DALYs for HAP were in Oceania; Eastern, Western in locations with high exposures (Supplemental and Central sub-Saharan Africa; and South Asia, Figure 53B). Age-standardized DALYs attributable to driven by differences in exposure. has yet to experience the benefits of PM 2.5 were higher than the global mean in East, DALYs attributable to PM 2.5 and HAP were higher Central, and South Asia; North Africa and the Middle in men, driven by sex differences in rates of the dis- East; and Southern and Western sub-Saharan Africa eases (Figure 20). Figures 56 and 57). These sex differences were less affected by air pollution (Supplemental In contrast to ambient PM 2.5, the burden attrib- pronounced for HAP given that women tend to be utable to HAP decreased sharply from 208 million more highly exposed. DALYs attributable to HAP had (95% UI: 162 to 259 million) DALYs and 4.36 million the largest impacts in infancy and early childhood, (95% UI: 3.33 to 5.40 million) deaths in 1990 to 91.5 whereas for PM2.5, it was between ages 30 and 90 million (95% UI: 67.0 to 119 million) DALYs and 2.31 years. million (95% UI: 1.63 to 3.12 million) deaths in 2019 Increased attention to air pollution as a CVD risk (Supplemental Figure 54A). Trends for both all-age factor is warranted and will require concerted ac- and tion and collaboration between government health age-standardized DALYs and death rates Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases F I G U R E 2 0 Map of Age-Standardized DALYs Due to Ambient Particulate Matter Pollution in 2019 DALYs ¼ disability-adjusted life years. and especially [95% UI: 180 to 209 million]) far exceeded the number relevant given high levels of exposure in many environmental agencies. This is of attributable YLDs (36.1 million [95% UI: 27.0 to parts of the world and links between PM2.5 and 46.0 million]), highlighting the outsized effect of to- health risks at levels substantially below those of bacco on premature mortality. current regulatory levels (41). As demonstrated in Progress in reducing tobacco use and exposure has North America and Western Europe, air quality not kept pace with competing demographic forces, management, coupled with regulation and enforce- namely, population growth and population aging. ment, is effective at reducing ambient air pollution Population growth, particularly in countries with a and its disease burden (42). Similar approaches large population of tobacco users, has resulted in an applied elsewhere, in combination with actions to increasing number of tobacco-attributable deaths and reduce emissions of climate-forcing agents will be DALYs since 1990. When controlling for population necessary. in- growth, decreases in both death and DALY rates are terventions, such as the use of portable air cleaners, In the observed. However, population aging has resulted in may be effective (43). Continued reductions in HAP smaller decreases in all-age rates compared to age- exposure through programs to improve access to standardized rates (Figure 21B). With approximately clean energy sources will lead to both health and 80% of current smokers living in LMICs, these de- climate benefits (44). mographic forces will continue to counter progress in TOBACCO. Tobacco, interim, including personal-level primary smoking, tobacco control for years to come. secondhand smoke, and use of chewing tobacco, In 2019, global smoking prevalence among men accounted for 8.71 million (95% UI: 8.12 to 9.31 was 33.5% (95% UI: 33.1% to 33.9%), and smoking million) deaths and 230 million (95% UI: 213 to 246 prevalence among women was 6.8% (95% UI: 6.6% to million) DALYs in 2019 (Figure 21A). Of tobacco- 7.0%). As a result of this difference, 75.4% of smoking attributable deaths, 36.7% were due to CVD. The attributable deaths occurred among men. The age number of YLLs attributable to tobacco (194 million pattern of tobacco use and exposure, combined with 3013 Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases F I G U R E 2 1 Total Numbers and Rates of Tobacco A B DALYs DALYs per 100,000 5,000 200 4,000 3,000 100 2,000 1,000 0 0 1990 2000 2010 1990 2019 Deaths 7.5 150 5.0 100 0.0 2000 2010 2019 YLDs 50 40 Rate per 100,000 Persons 200 1990 2000 2010 2019 Deaths per 100,000 10.0 2.5 Number (in Millions) 3014 50 0 1990 2000 2010 2019 YLDs per 100,000 800 600 30 400 20 200 10 0 0 1990 2000 2010 2019 1990 YLLs 2000 2010 2019 YLLs per 100,000 5,000 200 4,000 150 3,000 100 2,000 50 1,000 0 0 1990 2000 2010 2019 1990 Year 2000 2010 2019 Year Age-Standardized All Ages (A) Total number of DALYs, deaths, YLDs, and YLLs due to tobacco, 1990 to 2019. Shaded regions represent 95% uncertainty intervals. (B) Age-standardized and all-ages DALY, death, YLD, and YLL rates of tobacco, 1990 to 2019. Shaded regions represent 95% uncertainty intervals. Abbreviations as in Figure 1. Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases the age distribution of associated health outcomes, million) annual DALYs attributed to dietary risks results in age-specific DALYs peaking among men (Figure 22A). Worldwide, the absolute disease burden ages 60 to 64 years and among women ages 65 to 69 caused by dietary risks has risen for 30 years, years (Supplemental Figure 58). regardless of how measured. Over the same period, The highest age-standardized tobacco-attributable age-standardized rates have fallen for most measures, DALY rates among men were observed in Eastern indicating the central role of population growth and Europe, Central Asia, and Oceania (Supplemental population Figure 59). Among women, the highest rates were (Figure 22B). The exception is age-standardized rates observed in Oceania, high-income North America, of YLDs caused by dietary risks, which have grown in and Central Europe. Thirty percent of all current both absolute and proportional terms. smokers live in China, and nearly one-third of tobacco-attributable deaths occurred in China in 2019. aging on the observed increases Worldwide, the number of DALYs caused by dietary risks peaks between 55 and 70 years of age for both men and women, with a large excess of DALYs With more than 1 billion active tobacco users, the among men compared to women in every age group tobacco epidemic remains a central challenge to to 80 years old (Supplemental Figure 60). Age- global health. The global disease burden of tobacco standardized rates of DALYs caused by dietary risks use continues to increase, attributable in large part are highest in Central Asia, Oceania, and Eastern to population growth and falling most heavily on Europe and lowest in Australasia, HICs of the Asia LMICs, where the large majority of tobacco users Pacific, and Western Europe (Supplemental Figures 61 live. Tobacco control measures include increased and 62). Differences in age-standardized DALY rates taxes on tobacco, mass media education campaigns, among populations reflect a complex interplay be- bans on required tobacco marketing and sponsorship, tween variations in diet quality, levels of exposure to prominent warning labels on different dietary risks, and access to interventions tobacco products, required environments to be smoke-free, and ensuring access to and delivery of tobacco targeting the downstream clinical effects of CVDs. The detailed effects of many dietary risks are cessation treatments in health care systems. The poorly evidence-based measures are included in the World hampered by the challenges of accurately quantifying understood because assessments are Health Organization’s Framework Convention on exposures and separating the effects of each risk from Tobacco Control, a public health treaty that took those of important covariates. However, the effects of effect in 2005 and has been ratified by 182 countries. dietary risks on CVD remain large whether assessed as Despite this global commitment, adoption of the individual dietary factors or measures of overall diet Framework Convention on Tobacco Control mea- quality, and there is little doubt about the importance sures has varied widely across countries. Increasing of dietary risks as a cause of global disease burden. adoption and effective implementation of evidence- Strong commercial interests driving sales of based tobacco control policies is a key worldwide unhealthy foods have made it challenging to make public health priority. Looking ahead toward non- significant progress toward improving diet quality. communicable disease targets set in the Sustain- Easy access to healthy fruits, vegetables, and whole able Development Goals, accelerated progress in grains remains limited for much of the world. Many implementing proven policies and interventions is countries have adopted policies to limit consumption necessary of added sugar, sodium, and harmful fats, but to substantially reduce tobacco- attributable burden. implementation has mostly been weak, and the impact on global health has been limited. Exceptions DIETARY RISKS. In GBD 2019, dietary risks comprise are regulatory and fiscal interventions such as soda the sum of adverse effects of diets in which 15 food taxes and beverage reformulation programs that have types are either underconsumed (fruits, vegetables, led to lower intakes of added sugars, proving the legumes, whole grains, nuts and seeds, milk, fiber, feasibility of determined intervention. Likewise, the calcium, omega-3 fatty acids from seafood, and removal of artificial trans-fat from the food supply in polyunsaturated fatty acids) or overconsumed (red the United States has improved diet quality, although meat, processed meat, sugar-sweetened beverages, the amount of trans-fat in the global food supply re- trans-fatty acids, and sodium). mains high. Reliance on drug therapies targeting CVDs are the primary consequence of these dietary downstream metabolic risk factors caused by obesity risks, with 7.94 million (95% UI: 6.47 to 9.76 million) may be inadequate. Ill health caused by dietary risks annual deaths and 188 million (95% UI: 156 to 225 is anticipated to rise rapidly in LMICs over the coming 3015 Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases F I G U R E 2 2 Total Numbers and Rates of Dietary Risks A B DALYs DALYs per 100,000 250 4,000 200 150 3,000 100 2,000 50 1,000 0 0 1990 2000 2010 2019 1990 Deaths 10.0 200 7.5 150 5.0 100 2.5 0.0 1990 2000 2000 2010 2019 Deaths per 100,000 2010 2019 YLDs 30 20 Rate per 100,000 Persons Number (in Millions) 3016 50 0 1990 2000 2010 2019 YLDs per 100,000 400 300 200 10 100 0 0 1990 2000 2010 2019 1990 YLLs 2000 2010 2019 YLLs per 100,000 200 4,000 150 3,000 100 2,000 50 1,000 0 0 1990 2000 2010 2019 1990 2000 2010 2019 Year Year Age-Standardized All Ages (A) Total number of DALYs, deaths, YLDs, and YLLs due to dietary risks, 1990 to 2019. Shaded regions represent 95% uncertainty intervals. (B) Age-standardized and all-ages DALY, death, YLD, and YLL rates of dietary risks, 1990 to 2019. Shaded regions represent 95% uncertainty intervals. Abbreviations as in Figure 1. Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases years, and behavioral and policy interventions suited North America; and for women in Andean Latin for implementation at scale in diverse settings around America. the world are urgently required. LPA remains a major threat to public health, and LOW PHYSICAL ACTIVITY. LPA is an important risk factor for IHD, stroke, diabetes, breast and colon cancers, and other noncommunicable diseases. The combination of increased risk for important causes of mortality and significant levels of LPA in most countries has led to physical inactivity being characterized as a pandemic. LPA is an important contributor of premature mortality, morbidity, and DALYs for adults in most of the world. Globally, the total number of DALYs due to LPA, defined as <3,000 to 4,500 metabolic equivalent minutes per week, continuously increased from 8.61 million (95% UI: 4.28 to 15.9 million) in 1990 to 15.7 million (95% UI: 8.52 to 28.6 million) in 2019 the overall burden is increasing globally even as agestandardized rates are declining. Although few health systems have historically focused on LPA, there is increased awareness and attention being paid to LPA as exemplified by the 2018 World Health Organization Global Action Plan for Physical Activity. However, the factors that influence population physical activity largely reside outside of the health sector. Increasing physical activity will depend on effective partnerships and collaboration between health and sectors such as transportation, education, urban planning, workplace health strategies, and environmental protection. SUBNATIONAL DISEASE BURDEN (Supplemental Figure 63A). A linear trend was observed in the numbers of deaths due to LPA, reach- GBD 2019 estimates disease burden within countries ing 832,000 premature deaths (95% UI: 427,000 to as well as between countries. Figure 24 shows the 1,470,000 premature deaths) in 2019. During the same age-standardized rate of YLLs due to CVD for all time period, the estimated YLLs grew steadily from countries, with Brazil, China, India, Indonesia, Japan, 7.51 million (95% UI: 3.62 to 14.4 million) in 1990 to 12.7 Kenya, Mexico, the United States, and the United million (95% UI: 6.58 to 23.8 million) YLLs in 2019. Kingdom shown at the first subnational administra- Over time, the all-ages rate of DALYs, deaths, and tive level and Stockholm County shown separately YLLs due to LPA has increased, and the age- from the rest of Sweden. Subnational disease esti- standardized (Supplemental mation is made possible through collaboration with Figure 63B). This pattern reflects increased burden these governments. Subnational data reveal wide due to growth and aging of the population, an effect differences in DALYs within countries. For example, that is removed by age standardization. in Kenya in 2019, IHD DALYs were estimated to vary rate has decreased Total global DALYs due to LPA were similar for men from 342.7 per 100,000 (95% UI: 212.4 to 531.7 per and women until the 65- to 69-year age group, with 100,000) in Turkana to 1,215.4 per 100,000 (95% UI: men consistently higher (Supplemental Figure 64). 856.8 to 1,612.4 per 100,000) in Nyeri, a 112.0% dif- This pattern reversed in the 70- to 74-year age group ference within Kenya. IHD DALYs in India ranged as DALYs for women surpassed those for men. At all from 506.6 per 100,000 (95% UI: 379.6 to 819.0 per ages beyond 75 years, women had more DALYs than 100,000) in Mizoram to 5,413.2 per 100,000 (95% UI: men, presumably driven by greater survival among 4,316.9 to 6,389.9 per 100,000) in Punjab, a 165.8% women. LPA DALYs rose steadily for both men and difference within the country. In Brazil, IHD DALYs women beginning at age 25 years, peaking for both varied from 771.2 per 100,000 (95% UI: 679.4 to 866.3 sexes in the 80- to 84-year age group and declining per 100,000) in Amazonas to 2,416.2 per 100,000 (95% thereafter. UI: 2,176.7 to 2,686.2 per 100,000) in the Rio de Age-standardized DALYs due to LPA were highly Janeiro state, a 103.2% difference within the country. variable by both region and sex. The highest rates Within the United States, there was a 99.6% differ- were seen for both men and women in North Africa ence in IHD DALYs, ranging from 1,438.3 per 100,000 and the Middle East, Oceania, tropical Latin America, (95% UI: 1,210.7 to 1,699.0 per 100,000) in Utah to and the Caribbean (Figure 23), with high rates for men 4,293.1 per 100,000 (95% UI: 3,636.0 to 5,033.0 per also (Supplemental 100,000) in West Virginia. In Mexico, they ranged Figure 65). The lowest age-standardized DALYs for from 890.5 per 100,000 (95% UI: 752.2 to 1,073.3 per LPA were seen for both men and women in high- 100,000) in Quintana Roo to 2,315.1 per 100,000 (95% income Asia Pacific, Southern Latin America, and UI: 1,932.1 to 2,716.3 per 100,000) in Chihuahua, an Eastern subSaharan Africa; for men in high-income 88.9% difference within Mexico. Disease burden observed in Central Asia 3017 3018 Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases F I G U R E 2 3 Map of Age-Standardized DALYs Due to Low Physical Activity in 2019 DALYs ¼ disability-adjusted life years. attributable to elevated levels of metabolic risk fac- interventions and delivering resources where they tors also varies significantly within countries. will have the biggest impact. There is often a gap Further analysis of the variation of CVD burden between the identification of a problem, the location within countries will be vital to implementing health of a solution, and the translation of that solution to policies that reduce burden but also decrease dis- an entire population. We currently lack a systematic, parities. The strategies to deal with these inequalities scalable process for determining which interventions include: 1) targeting reduction in key modifiable risks are most likely to succeed in a given location, and including diet, tobacco, alcohol, physical activity, and research funding should be directed at addressing obesity; 2) improved access and quality of health care; this gap. and 3) a renewed focus on the social determinants of health. Addressing risk factors may prove to be an STUDY LIMITATIONS important initial opportunity to reduce disparities in parallel with broader efforts targeting social de- Estimates from GBD 2019 should be interpreted in terminants, with potential indirect benefits for light improving those social determinants, such as reduced although an essential source of data for public of several limitations. Death certificates, financial hardship due to fewer acute cardiac events health, may be misclassified given the difficulty of among working-age adults. identifying an underlying cause of death. GBD 2019 Several risks are increasing globally and warrant applies statistical methods to improve the compa- system attention, rability of health information coded using the ICD pressure, unhealthy system and continuously evaluates, improves on, cholesterol, and poor diet. Targeting subnational and reports the details of these methods. The use of locations where metabolic risks are rising rapidly different subnational population-based studies may may be an important approach for testing new lead to compositional bias of national estimates, increased policy and health including high BMI, blood Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases F I G U R E 2 4 Map of Age-Standardized YLLs Due to Cardiovascular Diseases in 2019 YLLs ¼ years of life lost. although GBD 2019 adjusts variance and weighting particular, better data are needed on the incidence to reflect this possibility. ICD system codes from of coronary events, cardiac arrest, and the severity administrative health facility data may represent a and associated disability of chronic heart and group of patients that differs from the standard case vascular diseases. Comorbidity of CVD and the joint definition for a disease, although GBD 2019 applies effects of multiple risk factors remains a topic adjustments to these data to account for differential where further investigation is also needed. access to health care and alternate case definitions. Access to CVD diagnostic technologies is likely to CONCLUSIONS AND RECOMMENDATIONS influence estimates of some conditions, with lower access resulting in lower observed prevalence. Some CVDs remain the leading cause of disease burden in commonly example, the world. CVD continues its decades-long rise for electrocardiogram for AF—will underestimate true almost all countries outside the high-income world disease prevalence. Estimates are reported with an and, alarmingly, age-standardized CVD rates have uncertainty interval that should always be carefully begun to rise in many locations where they were considered, given that it represents both data previously declining. There remains a large gap be- sparsity and differences in sample size across data tween identifying CVD as a problem, identifying the sources and study locations. However, uncertainty best package of solutions, and delivering them to the may be underestimated in locations where no data entire population. used diagnostic tools—for on CVD of any kind are available. Limited data on GBD 2019 continues to be a platform that allows CVD and resulting wider uncertainty intervals for tracking and benchmarking of progress in the reduc- parts of sub-Saharan Africa, Oceania, and Asia may tion of CVD burden. However, large investments are restrict our ability to interpret trends in burden still over time. An important use of GBD results is including the expansion of robust vital registration therefore to identify gaps in CVD health data and systems, reliable electronic health records, and health guide investments in future disease surveillance. In surveys to all countries. needed to improve disease surveillance, 3019 3020 Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 Global Burden of Cardiovascular Diseases High rates of excess mortality are currently being received honoraria from Akcea, Amgen, Sanofi, Esperion, Kowa, observed because of the global severe acute respira- Novartis, Ionis Pharmaceuticals, Mylan, Menarini, Merck, Recordati, tory syndrome coronavirus 2 pandemic, and much of Regeneron Daiichi-Sankyo, AstraZeneca, Aegerion, Amryt, and Sandoz; and has served as a consultant/on the Advisory Board for Akcea, this additional disease burden may be CVD due to the Amgen, Sanofi, Esperion, Kowa, Novartis, Ionis Pharmaceuticals, effects of both viral infection but also the unintended Mylan, Menarini, Merck, Recordati, Regeneron Daiichi-Sankyo, Gen- consequence of social distancing behaviors, such as zyme, Aegerion, and Sandoz. Dr. Coresh has received funding from changes in the delivery of health care (45,46). Further research in this area is urgently needed. the NIH and National Kidney Foundation; and has served as an advisor to Healthy.io. Dr. Fowkes has served on the Advisory Board for AstraZeneca. Dr. Muntner has received grants and personal fees CVD was the cause of 6.2 million deaths occurring between the ages of 30 and 70 years in 2019. There is a pressing need to focus on implementing existing cost- from Amgen Inc. Dr. Ribeiro has received partial support by CNPq (310679/2016-8 and 465518/2014-1) and by FAPEMIG (PPM-00428-17). Dr. Zuhlke has received funding by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) effective interventions and health policies if the under the MRC/DFID Concordat agreement and the National Research world is to meet the targets for Sustainable Develop- Foundation of South Africa. Dr. Rigotti has served as a consultant to ment Goal 3 and achieve at least a 30% reduction in Achieve Life Sciences; and has received royalties from UpToDate, Inc. Dr. Rodgers is employed by The George Institute for Global Health premature mortality due to noncommunicable dis- (TGI) and seconded part time to George Medicines Pty Ltd (GM); TGI ease by 2030. In the face of a global viral pandemic, has submitted patent applications with respect to low-fixed-dose we still must emphasize global commitments to combination products for the treatment of cardiovascular or car- reduce the suffering and premature death caused by diometabolic disease and is listed as one of the inventors; George Health Enterprises Pty. Ltd. (GHE) and its subsidiary, GM, have CVD, which limits healthy and sustainable develop- received investment funds to develop fixed-dose combination prod- ment for every country in the world. ucts, including combinations of blood pressure-lowering drugs; GHE ACKNOWLEDGMENTS This manuscript was pro- is the social enterprise arm of TGI (Dr. Rodgers does not have a direct financial interest in these patent applications or investments). Dr. duced as part of the GBD Collaborator Network and Sundström holds ownership in companies providing services to Itrim, in accordance with the GBD protocol. Additional Amgen, Janssen, Novo Nordisk, Eli Lilly, Boehringer Ingelheim, information can be found in the Supplemental Acknowledgments and Declarations. Bayer, Pfizer, and AstraZeneca, outside the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. AUTHOR DISCLOSURES ADDRESS FOR CORRESPONDENCE: Dr. George A. This study was funded by the Bill and Melinda Gates Foundation. Dr. Benjamin has received funding from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) Mensah, Center for Translation Research and Implementation Science, National Heart, Lung, and Blood (R01HL092577, 1R01HL128914) and American Heart Association Institute, National Institutes of Health, Rockledge I, (18SFRN34110082). Dr. Brauer has received a grant from the Bill and 6705 Melinda Gates Foundation. Dr. Catapano has received support from Bethesda, Maryland 20892-7960. E-mail: george. Fondazione Cariplo 2015-0524 and 2015-0564, H2020 REPROGRAM Rockledge Drive, 4th Floor, MSC 7960, GR-2011- mensah@nih.gov. OR Dr. Gregory A. Roth, Division 02346974, Ministry of Health - Ricerca Corrente Multimedica; has of Cardiology, Department of Medicine, and Depart- received research grant/support from Sanofi, Sanofi Regeneron, ment of Health Metrics Sciences, Institute for Health PHC-03-2015/667837-2, ERA NET ER-2017-2364981, Amgen, Mylan, Menarini, and Eli Lilly; has served on the speakers bureau for Akcea, Amgen, Sanofi, Esperion, Kowa, Novartis, Ionis Metrics and Evaluation, University of Washington, Pharmaceuticals, Mylan, Menarini, Merck, Recordati, Regeneron, 2301 5th Avenue, Suite 600, Seattle, Washing- Daiichi-Sankyo, AstraZeneca, Aegerion, Amryt, and Sandoz; has ton 98121. E-mail: rothg@uw.edu. REFERENCES 1. Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020;396:1204–22. 2. Mensah GA, Roth GA, Fuster V. The global burden of cardiovascular diseases and risk factors: 2020 and beyond. J Am Coll Cardiol 2019;74: 2529–32. 3. Mensah GA, Wei GS, Sorlie PD, et al. Decline in cardiovascular mortality. Circ Res 2017;120: 366–80. 4. Murray CJL, Aravkin AY, Zheng P, et al. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020;396:1223–49. 5. GBD Compare. Available at: https://vizhub. healthdata.org/gbd-compare/. Accessed November 11, 2020. 8. GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1923–94. 6. Global Health Data Exchange. Available at: http://ghdx.healthdata.org/. Accessed November 11, 2020. 7. Tolonen Hanna, Mähönen Markku, Asplund Kjell, et al. Do trends in population levels of blood pressure and other cardiovascular risk factors explain trends in stroke event rates? Stroke 2002;33:2367–75. 9. Husain MJ, Datta BK, Kostova D, et al. Access to cardiovascular disease and hypertension medicines in developing countries: an analysis of essential medicine lists, price, availability, and affordability. J Am Heart Assoc 2020;9:e015302. 10. Roth GA, Forouzanfar MH, Moran AE, et al. Demographic and epidemiologic drivers of global Roth et al. JACC VOL. 76, NO. 25, 2020 DECEMBER 22, 2020:2982–3021 cardiovascular mortality. N Engl J Med 2015;372: 1333–41. 11. United Nations, Department of Economic and Social Affairs, Population Division. World Population Ageing 2019: Highlights. ST/ESA/SER.A/430. Available at: https://www.un.org/en/ development/desa/population/publications/pdf/ ageing/WorldPopulationAgeing2019-Highlights. pdf. Accessed November 12, 2020. 12. United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects 2019: Highlights. ST/ESA/SER.A/ 423. Available at: https://population.un.org/ wpp/Publications/Files/WPP2019_Highlights.pdf. Available at: Accessed November 12, 2020. 13. Reynolds I, Page RL, Boxer RS. Cardiovascular health and healthy aging. In: Coll PP, editor. Healthy Aging: A Complete Guide to Clinical Management. Cham, Switzerland: Springer International Publishing, 2019:31–51. 14. Fuster V. Global burden of cardiovascular disease: time to implement feasible strategies and to monitor results. J Am Coll Cardiol 2014;64:520–2. 15. Gupta R, Wood DA. Primary prevention of ischaemic heart disease: populations, individuals, and health professionals. Lancet 2019;394: 685–96. 16. Zimmerman MS, Smith AGC, Sable CA, et al. Global, regional, and national burden of congenital heart disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Child Adolesc Health 2020;4:185–200. 17. Vekemans J, Gouvea-Reis F, Kim JH, et al. The path to group A Streptococcus vaccines: World Health Organization research and development technology roadmap and preferred product characteristics. Clin Infect Dis 2019;69:877–83. 18. Ammirati E, Cipriani M, Moro C, et al. Clinical presentation and outcome in a contemporary cohort of patients with acute myocarditis: multicenter Lombardy registry. Circulation 2018;138: 1088–99. 19. Ammirati E, Veronese G, Brambatti M, et al. Fulminant versus acute nonfulminant myocarditis in patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2019;74:299–311. Global Burden of Cardiovascular Diseases 23. Mofidi R, Goldie VJ, Kelman J, Dawson AR, Murie JA, Chalmers RT. Influence of sex on expansion rate of abdominal aortic aneurysms. Br J Surg 2007;94:310–4. 24. Forbes TL, Lawlor DK, DeRose G, Harris KA. Gender differences in relative dilatation of abdominal aortic aneurysms. Ann Vasc Surg 2006; 20:564–8. 25. Nienaber CA, Fattori R, Mehta RH, et al. Gender-related differences in acute aortic dissection. Circulation 2004;109:3014–21. 26. Cheitlin MD. Pathophysiology of valvular aortic stenois in the elderly. Am J Geriatr Cardiol 2003;12:173–7. 27. Stritzke J, Linsel-Nitschke P, Markus MRP, et al. Association between degenerative aortic valve disease and long-term exposure to cardiovascular risk factors: results of the longitudinal population-based KORA/MONICA Heart J 2009;30:2044–53. survey. Eur 28. Zilla P, Yacoub M, Zühlke L, et al. Global unmet needs in cardiac surgery. Glob Heart 2018;13: 293–303. 29. Flack JM, Kvasnicka JH, Gardin JM, Gidding SS, Manolio TA, Jacobs DR. Anthropometric and physiologic correlates of mitral valve prolapse in a biethnic cohort of young adults: the CARDIA study. Am Heart J 1999;138:486–92. 30. Freed LA, Levy D, Levine RA, et al. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med 1999;341:1–7. 31. Avierinos J-F, Gersh BJ, Melton LJ, et al. Natural history of asymptomatic mitral valve prolapse in the community. Circulation 2002;106: 1355–61. 32. Avierinos J-F, Inamo J, Grigioni F, Gersh B, Shub C, Enriquez-Sarano M. Sex differences in morphology and outcomes of mitral valve prolapse. Ann Intern Med 2008;149:787–94. 33. Rosenhek R, Rader F, Klaar U, et al. Outcome of watchful waiting in asymptomatic severe mitral regurgitation. Circulation 2006;113:2238–44. 20. Sliwa K. Heart failure can affect everyone: the 34. Tleyjeh IM, Abdel-Latif A, Rahbi H, et al. A systematic review of population-based studies of infective endocarditis. Chest 2007;132:1025–35. ESC Geoffrey Rose lecture. Eur Heart J 2020;41: 1298–306. 35. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ 21. Leon DA, Shkolnikov VM, McKee M, Kiryanov N, Andreev E. Alcohol increases circulatory disease mortality in Russia: acute and chronic effects or misattribution of cause? Int J Epidemiol 2010;39:1279–90. ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol 2018;71:e127–248. 22. United Kingdom Small Aneurysm Trial Participants, Powell JT, Brady AR, et al. Long-term outcomes of immediate repair compared with 36. Lavie CJ, Laddu D, Arena R, Ortega FB, Alpert MA, Kushner RF. Healthy weight and surveillance of small abdominal aortic aneurysms. N Engl J Med 2002;346:1445–52. obesity prevention: JACC health promotion series. J Am Coll Cardiol 2018;72:1506–31. 37. Jiang L, Manson SM, Beals J, et al. Translating the diabetes prevention program into American Indian and Alaska Native communities: results from the Special Diabetes Program for Indians Diabetes Prevention demonstration project. Diabetes Care 2013;36:2027–34. 38. Jousilahti P, Laatikainen T, Salomaa V, Pietilä A, Vartiainen E, Puska P. 40-year CHD mortality trends and the role of risk factors in mortality decline: the North Karelia project experience. Glob Heart 2016;11:207–12. 39. Johnson RJ, Wesseling C, Newman LS. Chronic kidney disease of unknown cause in agricultural communities. N Engl J Med 2019;380:1843–52. 40. Hammer MS, van Donkelaar A, Li C, et al. Global estimates and long-term trends of fine particulate matter concentrations (1998–2018). Environ Sci Technol 2020;54:7879–90. 41. Christidis T, Erickson AC, Pappin AJ, et al. Low concentrations of fine particle air pollution and mortality in the Canadian Community Health Survey cohort. Environ Health 2019;18:84. 42. Bennett JE, Tamura-Wicks H, Parks RM, et al. Particulate matter air pollution and national and county life expectancy loss in the USA: a spatiotemporal analysis. PLoS Med 2019; 16:e1002856. 43. Rajagopalan S, Brauer M, Bhatnagar A, et al. Personal-level protective actions against particulate matter air pollution exposure. a scientific statement from the American Heart Association. Circulation 2020 Nov 5 [E-pub ahead of print]. 44. Shupler M, Hystad P, Gustafson P, et al. Household, community, sub-national and countrylevel predictors of primary cooking fuel switching in nine countries from the PURE study. Environ Res Lett 2019;14:085006. 45. Vestergaard LS, Nielsen J, Richter L, et al. Excess all-cause mortality during the COVID-19 pandemic in Europe—preliminary pooled estimates from the EuroMOMO network, March to April 2020. Euro Surveill 2020;25:2001214. 46. Rodríguez-Leor O, Cid-Álvarez B, Ojeda S, et al. Impact of the COVID-19 pandemic on interventional cardiology activity in Spain. REC Interv Cardiol 2020;2:82–9. KEY WORDS cardiovascular diseases, global health, health policy, population health A PP END IX For a complete list of the GBDNHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group, supplemental methods, and supplemental figures, please see the online version of this paper. 3021